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Abstract
Fatigue is a common and major symptom in multiple sclerosis (MS). A number of
potential mechanisms exist as to the cause of MS-fatigue. These include that it is an
immune-mediated symptom or that it is due to neuroendocrine or autonomic dysfunction.
Studies have shown reduced activity in cortical and deep grey matter regions and
disruption of cortico-subcortical circuits has been theorised. This may lead to difficulty in
the planning or pre-movement stage of activity with compensatory overactivity
contributing to fatigue. Finally, dysfunction of the hypocretin system, deficiency of
which occurs in narcolepsy, has also been suggested. A number of deep grey matter
structures, including the basal ganglia, thalamus and hypothalamus, are implicated in
these mechanisms and the work presented in this thesis explores their role.
Conventional magnetic resonance imaging (MRI) techniques whilst crucial
in diagnosis and monitoring disease activity are generally felt to correlate poorly with
disability and symptomatology. Quantitative MRI techniques have been shown to provide
a more comprehensive evaluation of the extent of MS pathology and correlate better with
clinical deficit. Tl relaxation time measurement is one such quantitative MRI technique
and has been shown to demonstrate abnormalities in small structures such as the
pyramidal tracts and correlate with disability.
Firstly, we measured the T1 relaxation times of the thalamus and basal
ganglia in a cohort ofMS patients and assessed for any relationship with fatigue severity.
Secondly, in view of its key role in the autonomic, neuroendocrine and hypocretin
pathways, we performed the same measurement in the hypothalamus of a cohort of
patients and again assessed for any relationship to fatigue.
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Subsequently, to further evaluate any possible contribution from the
hypocretin system we measured cerebrospinal fluid (CSF) hypocretin-l levels in patients
with a number of neurological diseases including a cohort of MS patients and evaluated
for any relationship with severity of self-reported fatigue and hypersomnolence.
Studies in MS-fatigue, including those undertaken by our group,
traditionally rely on self-reported measures of fatigue severity. These questionnaire-based
measures are subject to a number of drawbacks including rater bias and lack of definition
of fatigue. In the final study, we assessed the effectiveness of the wakefulness-promoting
drug, modafinil, in MS patients with and without fatigue by assessing its effect on
objective measures of alertness and vigilance, including neurophysiological and
laboratory-based measures. In addition, in this study we evaluated any potential role of
the autonomic system in MS-fatigue.
We found significantly higher Tl relaxation times in a number of deep grey
matter structures including the thalamus, putamen and latterly the hypothalamus in MS
patients as compared to controls. The Tl relaxation time of the thalamus was higher in
fatigued patients as compared to non-fatigued patients and it correlated with fatigue
severity.
We found lower CSF hypocretin-l levels in patients with MS and
inflammatory disorders as compared to non-inflammatory conditions and this was
significant in the inflammatory cohort. However, we found no relationship with fatigue or
hypersomnolence severity. We did, however, detect a significant difference on a
sympathetic cardiovascular reflex test between fatigued and non-fatigued patients. Finally
we noted a significant improvement with modafinil, as compared to placebo, in a number
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of objective measures of alertness in patients with MS-fatigue and notably this was not a
class-effect.
To this extent, the findings from this thesis provide evidence for the
potential involvement of pathology in the thalamus in the mechanism of MS-fatigue,
possibly through disruption of cortico-subcortical circuits. In addition, in a separate
cohort of patients there was evidence of a relationship between autonomic disturbance
and fatigue. We have however found no evidence of a relationship between the
hypocretin system and fatigue in MS. Finally we have demonstrated supportive evidence
for a role for modafinil in the treatment of fatigue, a symptom for which, despite its
frequency and severity, there is often a paucity of treatment options available for MS
specialists.
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CHAPTER 1
Chapter 1. INTRODUCTION
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1.1 Multiplesderosis
Multiple sclerosis (MS) is a, predominantly T-cell-mediated, inflammatory disease of the
central nervous system (CNS). Pathologically it is characterized by destruction of myelin
within plaques that typically follow the course of blood vessels. Axonal loss occurs to
varying degrees in patients.
The history ofMS begins principally in the 1860s with Charcot's lectures
at the Salpetriere and what was then termed sclerose en plaques. However, earlier
descriptions can be found. A possible case of MS is that of Saint Lidwina of Scheidam
who is documented as having developed disability in 1396. The diary of Augustus d'Este
provides a personal account of MS over 2 decades beginning with an attack of bilateral
optic neuritis in 1822. Ollivier d' Angers in 1824 described a likely case in a text on spinal
cord disorders. The pathologists, Cruveilhier and Carswell both presented illustrations of
MS lesions in the 1830s. The German physician Frerichs named the condition
Himsklerose in 1849. Furthermore, Rindfleisch in 1863 described the perivascular
predominance of plaques.
Clinical features ofMS vary greatly, especially at the outset, indeed with a
significant proportion of patients being polysymptomatic. Physical features with motor,
co-ordination and sensory symptoms as well as specific syndromes localizing to the
brainstem and spinal cord and cognitive features such as memory impairment and
emotional lability occur frequently. MS-related fatigue, as Iwill detail, can be a physical
and/or mental complaint in individual patients.
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1.1.1 Pathophysiology
The characteristic feature ofMS is the demyelinated plaque. The classic lesion is sharply
demarcated with absent myelin and preserved axons within a matrix of glial scar tissue.
However some plaques, 'shadow plaques' do have, as well as demyelinated axons, axons
with abnormally thin myelin sheaths. These are felt to be areas of remyelination. In
chronic lesions there is often only a small rim of thinly myelinated fibres of
remyelination around the edge of the plaque. Also in chronic lesions an absence of
oligodendrocytes is usual whilst in early, acute disease, oligodendrocyte numbers are
preserved and remyelination is pronounced. The pattern seen in primary progressive MS
is different. Here oligodendrocytes are destroyed in a small ring outside of the plaque
edge suggesting that the primary process is that of oligodendrocyte destruction with
secondary demyelination[l].
Inflammation is present within the plaque but also within 'normal-
appearing' white matter (NAWM) and grey matter. The inflammatory infiltrate consists
mainly of T lymphocytes. Macrophages are also present and, in low numbers, B
lymphocytes too.
Axons are relatively but not absolutely preserved and axonal density is
reduced in most plaques. The extent of axonal loss varies significantly between patients
although is typically similar within different lesions in the same patient. Acute axonal
pathology, such as axon interruption and swelling, as well as axonal loss is also seen but
most commonly in acute, active MS. Axonal loss is important in that it is irreversible and
it is suggested that it underlies the progressive stage of the disease. On neuroimaging,
atrophy is the marker of axonal loss and certainly brain and spinal cord atrophy is felt to
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correlate better with disability than lesion load. The cause for axonal loss is uncertain.
Consequent to demyelination, loss of trophic support or increased susceptibility to
immune attack or cytotoxics, such as free radicals, are plausible suggestions[2].
MS is traditionally considered a white matter disease. Plaques are typically
distributed in the periventricular white matter and close to the brain surface, in the area
between the cerebral cortex and the sub-cortical white matter. Other common sites
include the optic nerves, cerebellar peduncles, pons, medulla and cervical spinal cord. As
with the pathological involvement ofNAWM, the grey matter is also frequently affected
and I will now detail this.
1.1.2 Grey matter involvement in MS
The presence of lesions within the grey matter has long been recognized. Brownell and
Hughes in 1962 reported the distribution of over 1500 cerebral plaques in the brains of 22
MS patients[3]. They described how 9010 of plaques were contained within grey matter
with 5% cortical lesions and 4% central grey matter. It was noted, however, that the
cortical plaques were almost all from a single case.
More recently, further evidence has accumulated of grey matter
involvement in MS from histopathological studies confirming both cortical and deep grey
matter lesions as well as microscopic abnormalities in normal-appearing tissue, such as
neuronal loss. One study evaluated an MS brain histologically and with imaging[4]. It
was found to have 14 (4.3%) cortical lesions. Magnetic resonance imaging (MRI)
however only picked up two of these pathologically identified lesions. In the same study
a further 12 brains were evaluated solely histologically. This arm of the study, found 106
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cortical lesions with a further 372 involving both cortex and subcortical white matter.
Peterson et a1looked at tissue blocks from 50 MS patients specifically to identify cortical
lesions of which 112 were detected[5]. Cortical lesions were noted to be hypocellular
compared to white matter lesions. The hypothalamus was investigated by Huitinga et at
and found grey matter lesions in 3 of 17 bypothalami[ 6]. A separate study looked at the
thalami of 10 MS patients and estimated a 35% neuronal loss as compared to controls[7].
As indicated above by the study of Kidd et at conventional MR1
techniques, such as T2-weighted imaging, are more likely to identify white matter than
grey matter lesions. More advanced MRI sequences are better at identifying grey matter
disease. Fluid-attenuated inversion recovery (FLAIR) MR1 is more sensitive to detecting
corticallesions[8]. Proton magnetic resonance spectroscopy eH-MRS) of cortical grey
matter demonstrated reduced N-acetylaspartate (NAA)[9]. Low NAA has been correlated
with axonal loss or dysfunction[IO]. Focal, as well as more global, cortical atrophy was
demonstrated in MS patients, even those with only short disease duration[ll, 12].
Magnetization transfer (MT) and diffusion-tensor (DT) imaging of grey matter has
demonstrated varied results. A study involving MT imaging of both the basal ganglia and
cortical grey matter revealed significantly reduced magnetization transfer ratio (MTR) in
MS patients[13]. Another study, however, found no significant difference between MS
patients and controls[I4], whilst a further study showed significantly increased fractional
anisotropy in the deep grey matter and reduced mean diffusivity in the putamen[ 15].
Previous studies also employed IH_MRS to investigate the deep grey matter. MS patients,
relative to controls, demonstrated a reduction in NAA concentration, in the thalamus, of
between II and Ic}o/o,as well as a 17 - 25% lower thalamic volume[7, 16]. These results
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were supported by post-mortem findings that revealed significant thalamic neuronal loss.
Positron emission tomography (PET) studies also demonstrated abnormalities with
reductions in the cerebral glucose metabolic rate (CMRGlu) in the grey matter of MS
sufferers[11]. This has been demonstrated both in the cortex as well as the thalamus,
putamen and head of the caudate nucleus.
1.2 Fatigue
Fatigue is an ill-defined complaint forwarded by patients with a wide variety of medical
conditions. In-fact, it is a frequent complaint amongst the general working population. In
one study of the primary care population, up to 200/0of men and 25% of women complain
of always feeling tired[18]. Within the medical population, fatigue is a major feature of,
amongst other diseases; chronic fatigue syndrome, sleep disorders, depression, infectious
diseases, autoimmune and endocrine disorders, neuromuscular diseases, epilepsy,
Parkinson's disease and malignancy.
Both patients and health professionals use the term fatigue, within these
conditions, to refer to a variety of concepts including; lethargy, tiredness, sleepiness,
weakness, lack of motivation as well as reduced mental and physical endurance. This
imprecision ensures that the study of fatigue as a symptom remains difficult. This should
not however detract from its importance.
1.3 MS-related fatigue
As previously described, MS has both physical and cognitive effects. Indeed, fatigue in
MS, as in other medical conditions, has been characterised in both mental and physical
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terms. Various MS investigators have defined fatigue as a feeling of weakness, tiredness
out of proportion to the level of exertion, lack of capacity to generate sufficient muscle
force and inability to sustain mental performance.
To provide consensus, in 1998 the Multiple Sclerosis Council for Clinical
Practice Guidelines published a definition of fatigue as a subjective lack of physical
and/or mental energy that is perceived by the patient 07 caregiver to interfere with usual
and desired activities[ 19].
The panel also sought to distinguish acute from chronic fatigue. Acute
episodes of fatigue are commonly associated with relapses, concomitant infections and
acute changes in weather and may of course be managed differently. It labeled chronic
fatigue as that present for any amount of time on 50% of the daysfor more than 6weeks
whilst acute fatigue was a new or significant increase in feelings of fatigue in the
previous 6weeks[19].
A number of features are felt to distinguish MS-related fatigue from that
which is experienced by the normal population[ 19]. These are:
• Comes on easily
• Exacerbated by heat
• Prevents sustained physical activity
• Interferes with responsibilities
• Interferes with physical functioning
• Causes frequent problems
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This contrasts with a number of features that are felt to be unhelpful in
differentiating MS-related fatigue to that experienced by the normal population. These
features include exacerbation with stress or depression, diurnal variation i.e. worse in the
afternoon and improvement with rest, sleep or positive experiences.
1.3.1 Epidemiology
Fatigue is undoubtedly a common and major symptom. Fatigue is reported by 78 - 86%
of MS patients[20, 21]. In studies it has been found to be the single most commonly
reported symptom above all other physical or mental complaints[20]. It frequently is the
presenting symptom[21].
Fatigue is ranked as one of the three worst symptoms by two thirds of MS
patients[21]. It is a frequent cause ofunemployment[22]. It interferes with activities of
daily living. It can affect other symptoms ofMS and has a significant impact in quality of
life studies[23, 24].
1.4 Measuring fatigue
Multiple techniques exist to measure MS-fatigue in both a subjective and an objective
fashion.
1.4.1 Subjectivemeasures
These methods rely on patients interpreting their level of fatigue and its impact. They
consist predominantly of questionnaires and rating scales. Numerous validated self-report
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tools exist within the literature. They vary from simple, single-item visual analogue
scales to 83-item questionnaires.
The Fatigue Severity Scale (FSS), I propose, is the most widely used
fatigue-self-report measure used in MS studies[23]. It is a nine-item scale with each item
being graded between 1 - 7 whereby 1 indicates strong disagreement and 7 strong
agreement. The result is presented as either the mean or sum score. It is routinely
suggested that the questions apply to your perception of fatigue over the preceding two
weeks. Generally as a guide a mean score greater than 4 indicates fatigue whilst a score
of 5 indicates severe fatigue. It has shown high reliability and validity and has been
applied in both cross-sectional and longitudinal studies[23].
The benefits of using such a scale are that it is brief as well as easy to
comprehend and employ for both health professionals and patients alike. Drawbacks
include rater bias, fluctuation and lack of a definition of fatigue. In addition, there is a
potential ceiling effect that could become particularly apparent in longitudinal studies.
1.4.2 Objective measures
These are performance-related measures that aim to quantify the level of fatigue. Tools
have been applied in studies to assess both mental and physical fatigue.
Physical fatigue has been assessed in a variety of manners. One such
example is recording maximal isometric voluntary contraction of certain muscles for a set
period and calculating a so-called Fatigue Index, which is the decay in maximal force
during exercise[25]. An alternative method involves repetitive electric and transcranial
magnetic supramaximal stimulation of certain muscles during sustained exercise and
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observing for any change in the force of the response[26]. Motor evoked potentials have
been used as a further neurophysiological method of quantifying physical fatigue[27].
Assessment of cognitive fatigue has been undertaken in a variety of ways.
Cognitive function as measured by a wide-ranging neuropsychological assessment has
been undertaken in MS patients with assessment performed before and after a
continuously, cognitively-effortful task[28]. Neurophysiological methods have been
applied. Measuring evoked brain potentials in response to certain stimuli for example an
auditory target-detection task has been used[27].
1.5 Pathophysiology or Ms-ratigue
MS-related fatigue can be further defined according to the presumed pathophysiology as
primary and secondary fatigue.
1.5.1 Setondary Ms-ratigue
Secondary fatigue is that which is attributable to other MS-related factors. A number of
factors have been proposed. Deconditioning, the idea that fatigue is due, in part, to
impaired muscle performance due, for example, to muscle changes secondary to upper
motor neuron involvement or muscle disuse with disability. Certainly exercise programs
are commonly used in the management of fatigue. Specific respiratory muscle weakness
has been identified as a potential cause of reduced exercise capacity[29, 30].
Pharmacological agents used to treat other MS-related symptoms could very well
contribute to fatigue. Similarly pain or poor sleep due to any number of factors could also
contribute to secondaryMS fatigue
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1.5.2 Primary MS-fatigue
This term is used to describe that which is felt to be directly attributable to the disease
process. Investigators may use the term central fatigue too. There are multiple proposed
mechanisms for the underlying cause of primary MS-related fatigue and Iwill detail them
in the following paragraphs.
1.5.3 Immune disorder
The strongest evidence for this is that fatigue is a common and disabling symptom
amongst autoimmune disorders, for example, systemic lupus erythematosus (SLE)[31].
As with MS, fatigue can signify the onset of an SLE relapse. A number of laboratory-
based studies have looked for evidence that immune system activity has a role in MS-
related fatigue and have revealed inconsistent results.
Heesen et al looked at 15 MS patients with fatigue and 15 without, as
determined by FSS scores[32]. They measured serum levels of production of pro-
inflammatory cytokines, tumour necrosis factor a (TNFa) and interferon-y (IFN-y), as
well as the anti-inflammatory cytokine interleukin (IL)-IO. Both TNFa and IFN-y were
significantly higher in the fatigue group. In addition, both cytokines correlated with a
self-reported fatigue score when corrected for disability, disease duration, disease
severity and progression, depression and treatment with interferon. A similar study by
Flachenecker et at assessed the mRNA expression of the same cytokines in 26 patients
with MS-related fatigue and II patients without[33]. TNFa mRNA levels were
significantly higher in the fatigue cohort. It is of note that there is some evidence that
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TNFa has been shown to be higher in patients with active MS as compared to those with
stable disease[34].
Another study evaluated different inflammatory markers, serum C-reactive
protein and soluble intercellular adhesion molecule-l as well as urinary neopterin
excretion, in 38 MS patients[35]. There was no correlation of any of these laboratory
markers with fatigue scores as determined by the FSS.
A small study by Bertolone et al reports an improvement in fatigue scores
in MS patients paralleling a decrease in serum levels ofIL-IP, soluble IL-2 receptor and
IL-6[36]. A further study also found higher levels of serum markers of immune activity in
MS patients with fatigue as compare to those non-fatigue patients[31]. The markers were
B2 microglobulin, soluble IL-2 receptor and soluble CD8. Rudick and Barna, however,
reported no association of IL-2 and soluble IL-2 receptor with fatigue in 8 MS
patients[38].
Also of note is the randomized, double-blind, placebo-controlled,
crossover trial by Wingerchuk et al of high-dose aspirin in which the response of MS-
fatigue was assessed[39]. Fatigue scores were found to be lower during aspirin treatment.
One potential mechanism for this improvement is the effectiveness of aspirin in treating
cytokine-mediated processes.
In addition, aspirin as well as other non-steroidal agents and, at times,
corticosteroids are used for deteriorations associated with the administration of immune-
modifying treatment, interferon-beta, in MS. These deteriorations, termed flu-like
episodes, often feature prominent fatigue, are possibly related to increased cytokine levels
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and provide further evidence for an immune process being involved in MS-related
fatigue.
1.5.4 Neuroendocrine
It has been felt that neuroendocrine disturbance particularly of the hypothalamic-
pituitary-adrenal (HPA) axis plays some role in the pathophysiology of MS-related
fatigue. Studies in chronic fatigue syndrome (CFS), a condition characterized by
disabling fatigue, have shown low levels of cortisol and hypoactivity of the adrenal gland
to stresses[40). In addition, patients with other autoimmune inflammatory conditions,
such as rheumatoid arthritis, have been shown to have a hyperactivity of the HP A axis
and a poor response to stress[41, 42].
A study of 52 MS patients evaluated the HP A axis with a battery of tests
and found evidence of central upregulation of HP A activity that may be associated with
active inflammation[43). In addition, in the secondary-progressive MS sub-group, there
was a reduction in the lIP A response to stress that may be a consequence of the disease or
chronic activation by corticosteroids. However, the presence or absence of fatigue was
not found to be associated with any hormonal measures.
Heesen et at, within the trial mentioned earlier, evaluated the HP A axis
activity of 15 patients with MS fatigue and 15 without[32]. There was no difference
found between the groups although, there was a trend for a correlation between baseline
cortisol level and FSS score. However, another study looked at 31 MS patients of which
15 patients had fatigue and 16 had no fatigue. This group found a significant association
between the presence offatigue and hyperactivity of the IIPA axis[44].
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Of note is that one study also evaluated the hypothalamic-pituitary-
gonadal axis amongst its battery of investigations[ 43]. They found that 24% of male MS
patients (age 32 - 40 years) had a low serum testosterone levels. Fatigue is a common
symptom in patients with testosterone deficiency.
1.5.5 Autonomic nervous system dysfunction
MS causes autonomic nervous system dysfunction with the most common reported
symptoms being that of bladder and sexual dysfunction. However, other systems are
affected. In one study of 63 MS patients, an abnormality, other than bladder,
gastrointestinal and sexual disturbance, was found in 56% of patients on autonomic
investigations[45]. Twenty-nine percent of patients had an abnormal cardiovascular test
with 18% classified as having autonomic dysfunction, defined as abnormalities found on
two or more autonomic tests (not including bladder function). Another study found
autonomic cardiovascular dysfunction in 27010ofMS patients[46]. This is despite only a
much smaller proportion of MS patients actually complaining of specific cardiovascular
symptoms such as syncope. There has been some suggestion that there is an increase in
autonomic dysfunction with increasing disability and also with chronic progressive MS
however this correlation has not seen in all studies[45, 46].
The observation that symptoms of autonomic dysfunction, for example,
weakness, exhaustion and cognitive diffirulties and the relationship of such features to
environmental factors, such as heat, has led investigators to hypothesise that autonomic
dysfunction may contribute to fatigue. In addition, autonomic dysfunction has been
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identified in CFS patients and treatment of orthostatic hypotension improves fatigue
symptoms in CFS sufferers[47].
Studies of fatigue and autonomic dysfunction in MS patients have
typically shown conflicting results. Merkelbach et al looked at 84 MS patients, 64% of
whom suffered from fatigue[46]. There was no significant difference in fatigue scores
between patients with and without cardiovascular autonomic dysfunction. Flachenecker
et at, on the other hand, in a study of 60 MS patients, 45% of whom suffered from
fatigue, found that cardiovascular autonomic dysfunction only occurred in those with
MS-related fatigue[ 48]. There was evidence of significant differences in both
parasympathetic and sympathetic tests between patients with and without fatigue. On
further analysis, there appeared to be a more specific association between fatigue and
sympathetic dysfunction.
1.5.6 CNSmechanisms
There is evidence from several studies of a central or CNS origin to fatigue, separate to
the proposed neuroendocrine and autonomic nervous system dysfunction already
discussed. I will detail evidence and hypotheses now and in the following sub-chapter.
Investigators have employed a variety of neurophysiological techniques.
Leocani et at studied 32 MS patients using electroencephalography (EEG) with
electromyography (EMG) during a simple motor action[ 49]. Results suggested
impairment of cortical structures involved in motor planning in patients with MS-related
fatigue. It was theorized that compensatory overactivity may occur in certain regions,
such as frontal structures, and this in tum may lead to central fatigue.
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Sheean et al employed transcranial magnetic stimulation (TMS) with EMG
in 21 patients[26]. A decline in maximal voluntary force (MVF) during isometric muscle
contraction was found and was paralleled by a decline in central activation. TMS
immediately post-exercise revealed that the stimulated twitch force in patients was the
same as pre-exercise. In controls, the MVF also declined but less rapidly and the post
exercise stimulated twitch force of the muscle was significantly reduced. This suggested
that fatigue in MS was central as opposed to the peripheral, muscular, fatigue of normal
subjects.
TMS was also employed by Perretti et al in 41 MS patients[50]. Normally,
after fatiguing exercise, the motor evoked potential produce by TMS decreases in
amplitude. In this study, however, this decrease in amplitude did not occur in the MS
group. This result was felt to support an intracortical dysfunction on the basis that this
phenomenon has an intracortical origin.
Finally, Sandroni et al performed cerebral and spinal root magnetic
stimulation in 10 MS patients with each patient being tested in a 'normal' and 'fatigued'
state[27]. No significant difference was found in the central motor conduction time
(difference in latency between the motor evoked potential produced by cerebral and root
stimulation). Additional assessment of reaction times and brain evoked potentials to an
auditory target, in the same two states, were also performed. Again evoked potentials did
not differ between rested and fatigued states, however, reaction times during the task
became significantly prolonged in the fatigued state. This suggested that the difficulty in
the fatigued state was due to dysfunction in the planning or pre-movement stage rather
than the stimulus evaluation or the initiation of movement stages.
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MRI has also been used to investigate for a potential central mechanism in
MS fatigue. Conventional MRI techniques, in particular T2-weighted imaging, have
traditionally focused on white matter abnormalities and have become the main
paraclinical tool for diagnosing MS. Studies have demonstrated that abnormalities
detectable on proton density- (PD) or T2-weighted imaging have, at best, a limited role in
the pathogenesis of MS-related fatigue. Colombo et al found a significant correlation
between fatigue severity and MRI lesion burden on PD-weighted imaging[51]. Other
studies, however, have detected no association between fatigue and T2 hyperintense or
TI hypointense lesion loads and nor has the number of gadolinium (GAD)-enhancing
lesions been shown to be an important factor[17, 52, 53]. Furthermore, no correlation has
been found with either any regional or global atrophy measure[17, 52].
1.5.7 Deep grey matter involvement
The potential role of the deep grey matter in the pathogenesis of fatigue has been
demonstrated in other pathologies. An MRI based study of post-polio-fatigue patients
revealed a significant correlation between fatigue severity and the presence of
hyperintense areas within the white matter and grey matter, including the putamen[54].
Fatigue and somnolence, often transient, are reported side effects of stereotaxic surgery
involving the thalamus and the globus pallidus[55, 56]. A meta-analysis of reports of
various lesions, including cerebrovascular insults and tumours, affecting the basal ganglia
revealed that the commonest disturbance subsequent to damage of the caudate nucleus
was abulia[ 57].
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The hypothalamus is also implicated as having a potential role in MS-
related fatigue through a variety of mechanisms. These have been discussed in some
detail above including via the neuroendocrine axis and autonomic dysfunction. A further
potential mechanism is that of hypersomnia and this will be discussed in more detail in a
future sub-chapter.
Investigators have used different neuroimaging techniques to assess the
deep grey matter in MS patients. In a cohort of relapsing-remitting MS subjects, Filippi et
al employed functional MRI (tMRI) and found that, during a simple motor task, patients
with fatigue showed significantly lower, relative activation of the ipsilateral cerebellar
hemisphere and rolandic operculum and the contralateral middle frontal gyrus and
thalamus[58]. In addition, there was a significant inverse correlation between fatigue
severity and the activity in the contralateral thalamus and ipsilateral rolandic operculum.
A PET study by Roelcke et at revealed reductions in CMRGlu in MS patients with severe
fatigue, as compared to those without fatigue, in several areas[ 17]. This CMRGlu
reduction was evident in the prefrontal cortex, premotor cortex and supplementary motor
area as well as the putamen and head of the caudate nucleus. Significantly lower
CMRGlu was also seen in the internal capsule and white matter adjacent to the prefrontal
cortex. The results of both these studies appeared to imply a role for the deep grey matter
structures in the pathophysiology of MS-related fatigue. A purported mechanism is the
disruption of cortieo-subcortical circuits linking cortical grey matter with the basal
ganglia and thalamus[S8]. This dysfunction may lead to over-activity in alternative
pathways to enable motor programming with this compensatory mechanism contributing
to fatigue.
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1.6 Excessivedaytime sleepiness
Sleepiness is a high physiological drive toward sleep. It obviously is a normal experience
for most individuals. Excessive daytime sleepiness (EDS), however, is abnormal and is
that which interferes with normal activities of daily living. Patients suffering from EDS
will often describe either a constant feeling of sleepiness or an irresistible propensity to
sleep attacks.
EDS is a common complaint of people suffering from insufficient or
disrupted sleep or for those suffering from a primary sleep disorder. The International
Classification of Sleep Disorders (lCSD-2) describes the wide variety of diagnoses that
may have hypersomnia as a prominent feature[59]:
I. Insomnias
II. Sleep-related breathing disorders
m. Hypersomnias of central origin
IV. Circadian rhythm sleep disorders
v. Parasomnias
VI. Sleep related movement disorders
These categories include relatively common conditions such as narcolepsy
with or without cataplexy, obstructive sleep apnoea-hypopnoea syndrome (OSAHS) and
restless Jegs syndrome.
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1.7 Measuring EDS
Similar to measurements of fatigue, there are both objective and subjective tools
available.
1.7.1 Subjectivemeasures
As with fatigue measures, these consist predominantly of questionnaires and similarly
there are numerous published tools. Examples include the Stanford Sleepiness Scale
(SSS) and the Epworth Sleepiness Scale (ESS).
The ESS is the most commonly used questionnaire both experimentally
and clinically[60]. It rates sleep propensity in eight various, sedentary situations during
recent times. Each item is rated between 0 - 3 whereby 0 is 'would never doze' and 1,2
and 3 indicate slight, moderate and high chance of dozing respectively. A distinction is
made between dozing and simply feeling tired. Scores, therefore, range from 0 - 24. An
ESS score> 10 indicates hypersomnolence whilst> 16 indicates a high level ofEDS.
It has been shown to be valid and reliable and to significantly distinguish
normal subjects from patients with variety of conditions including narcolepsy and
OSAHS[60, 61]. It allows monitoring of treatment effects for example improvement in
patients with OSAHS when administered nasal continuous positive airways pressure
(CPAP)[61]. It may even allow the clinician to distinguish moderate or severe OSAHS
from mild OSAHS although this idea is disputed by other studies[60, 62]. Scores have
been shown to correlate significantly with sleep latency as measured during the Multiple
Sleep Latency Test (MSLT) although this again has been questioned by other studies[60,
62,63].
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Other benefits include that it is brief and simple to administer. It has also
been suggested it may overcome the component of daytime sleepiness that may be more
temporary, for example, related to the time-of-day or possibly the effects of drugs.
Drawbacks again include rater bias as well as possible gender bias with a study having
suggested that men may not report subjective sleepiness as often as women[63].
The SSS provides an immediate assessment of how alert you are
feeling[64]. The subject chooses which of seven descriptions currently represents their
level of alertness. It is obviously very quick to administer and provides an immediate
indication which may be usefully in studies to assess immediate responses to treatments.
However, it is susceptible to time-of-day variation and rater bias. In addition it may be
less applicable clinically when assessing overall response to treatments.
1.7.2 ObjectivelDeasures
The MSLT is the gold-standard measure of the degree of sleepiness on the day of
assessment[65]. It consists of a series of four-to-five, 20-minute daytime naps in
conditions that are conducive to sleep. The latency to sleep onset is recorded.
Unfortunately it is expensive as well as time-consuming for both patient and investigator.
A nonnal sleep pattern has to be maintained for one-week prior to testing. In addition, a
polysomnogram (pSG) should be performed the night before testing to look for causes
that may lead to EOS and confirm adequate sleep is obtained. An MSLT latency of < 8
minutes is consistent with EDS whilst a latency of < 5 minutes indicates severe EOS.
Other measures are also taken including the number of sleep-onset REM periods
(SOREMP) with ~ 2 SOREMPs supportive, although not alone diagnostic, of narcolepsy.
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A variant of this is the Maintenance of Wakefulness Test (MWT)[66]. In
this investigation the patient is asked to remain awake for 40 minutes in dim light and in a
semi-reclined position. Again it remains relatively time-consuming and expensive. The
MWT is less frequently used although it is sometimes the choice investigation for
example by employers such as airlines.
Critical Flicker Fusion Frequency (CFFF) is a tool employed quite
frequently in psychopharmacology[67]. During the investigation the subject determines
the frequency at which a flickering light appears to be a continuous steady light. It is felt
to assess the level of tonic CNS alertness and vigilance.
Pupillography is a further neurophysiological investigation to assess
alertness and will be discussed in detailed in the following sub-chapters.
1.8 PupiIJognpby
In subjects with decreasing alertness there is a characteristic, spontaneous pupillary
behaviour in darkness. Whilst alert the pupil remains relatively large and stable with
minimal oscillations in diameter. These changes in diameter are typically less than
0.3mm with a frequency of approximately 1 Hz. However with drowsiness the pupil size
gradually diminishes and there are slow oscillations, less than 0.5 Hz, of diameter that are
of gradually increasing amplitude and which can reach several millimetres. These have
traditionally been termed 'fatigue waves' although some authors have suggested
sleepiness waves as being more accurate[ 68].
This observation is the basis for the Pupillographic Sleepiness Test (pST)
in which a patient has their pupil size constantly monitored via infrared video
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pupillography whilst in a quiet, dark environment[69]. Typically three measurements are
derived, the total power of fluctuations (a measure of the total amplitude of low
frequency pupillary movements), the mean pupil diameter for a data segment and the
pupillary unrest index (PUI). The Pl.ll is the cumulative distance moved by the pupil
margin per minute. Both the PUI and power will increase with diminishing alertness
whilst the mean pupil diameter will decrease
1.8.1 Pathopbysiologicalbuis offatipe waves
Pupil constriction occurs due to contraction of the circular smooth-muscle fibres of the
sphincter pupillae via activation of the parasympathetic system. For example in the light
reflex, impulses travel from the retina, via the optic nerve to the optic tract. From there
they diverge toward the midbrain to synapse in the pretecta1 nuclei and then to both
Edinger-Westphal nuclei (EWN) in which the cell bodies of the parasympathetic
preganglionic neurons lie. From here the impulses travel to synapse, in the ciliary
ganglion within the orbital apex, with the postganglionic parasympathetic fibres which
travel to the sphincter pupillae. It is of note that the sphincter provides a much greater
force on pupillary size than the pupillary dilator muscle.
Pupillary dilatation occurs via two processes; activation of peripheral
sympathetic innervation of radial muscle fibres of the dilator papillae and central
inhibition of the EWN. This central inhibition is currently felt to be mediated by two
pathways which project from brain stem nuclei to the EWN. The first is a GABA-ergic
pathway from the All A5 nuclei to the EWN which passes by way of the hypothalamus.
The second is a noradrenergic pathway from the locus coeruleus (Le) to the EWN. It is
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of note that, amongst other sites, hypocretin-containing neurons project from the
hypothalamus to the LC.
A dynamic equilibrium normally maintains pupillary size. With sleepiness,
central inhibition of the EWN reduces and there is an unstable drift of central sympathetic
activation. This leads to increasing miosis and the instability underlies the pupillary
fatigue waves.
1.8.2 Pupillograpby and sleepiness
The question of whether pupillography can be used as an indicator of sleepiness has been
investigated in a number of studies both in normal individuals and patients.
Danker-Hopfe and colleagues, employed pupillography, the SSS
questionnaire and a modified MSL T at 2-hour intervals throughout a 16-hour day in 12
healthy, non-sleep-deprived individuals[70]. The study demonstrated that, for time-of-day
variations in sleepiness, the PUI and mean pupil diameter correlated with sleep latency.
The physiological assessments did not, however, correspond with the individual's
subjective assessment of their sleepiness.
A study by Wilhelm et al involved performing pupillography and
completing the SSS questionnaire 2-hourly in a cohort of 13 healthy but sleep-deprived
subjects[71). Over the course of 10 hours the PUI, power of fluctuations and subjective
rating all increased significantly whilst the mean pupil diameter became significantly
smaller. Whilst the SSS values also increased over the study period, there was, however,
no correlation between the SSS scores and the pupil data.
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A further study by the same group involved the same investigations in
healthy controls repeated 2-hourly over a 30-hour period of extended wakefulness and
demonstrated a similar pattern of PUI values and pupil diameter over the course of the
investigation[72]. This study did also show a significant correlation of subjective scales
with pupillography results in that higher SSS scores were associated with higher PUI
values.
Regen et al also looked at pupillography in healthy subjects and found that
changes in PUI correlated with distinct changes in the waking EEG, when both
investigations were performed 2-hourly, during a period of extended wakefulness[73].
Pupillography has also been studied in small numbers of patients with a
variety of conditions. Merritt and colleagues assessed cohorts of narcoleptics, patients
with OSAHS and healthy controls with pupillography and concurrent EEG(74]. Only the
mean pupil diameter was measured on pupillography. They found that there was a
significant increase in the amount of slow-wave activity with increasing pupillary miosis
in sleep-disordered patients although not controls.
McLaren et al studied patients with narcolepsy and idiopathic
hypersomnia, as well as healthy controls, with pupillography and MSLT[75]. They found
that sleep latency was significantly correlated with PUI. Grouping patients according to
the severity of their sleepiness, based on the shortness of their sleep latency, revealed that
the median PUI was greatest in the patients with severe sleepiness. Wilhelm et al also
performed pupillography in hypersomniacs (narcolepsy and OSAHS) and seven
controls[76]. There was a significant difference in PUI and power between patients and
controls.
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Pupillography has the benefit of being a quick, relatively simple objective
investigation which is closely related to the gold-standard investigation of sleepiness, the
MSLT. In fact it is felt to reflect the same physiological aspect of sleepiness as the
MSLT. It has been shown to detect differences between hypersomniacs and controls and
can also document the effect oftreatments[75-77].
1.8.3 PupllJograpbyand MS
There has been limited use of pupillography in studies involving MS patients. Egg and
colleagues investigated whether pupillography variables, principally as measures of
autonomic instability, were related to MS fatigue[7S]. The cohort of 51 MS patients
included those with a single clinical attack, relapsing-remitting, primary- and secondary-
progressive MS patients. It is of note that seven patients were suffering from an acute
relapse at the time of the study and IS patients were on disease modifying or
immunosuppressant treatment. There was also a cohort of 22 healthy volunteers although
not sex-matched. The investigation protocol involved questionnaires including the SSS,
Modified Fatigue Impact Scale (MFIS) and FSS as well as pupillography to determine the
PUI, their preferred outcome. Thirty-four (6']010)of the MS patients had severe fatigue
according to the FSS as compared to six (2']010)of the control group. None of the patients
or controls suffered from hypersomnolence as determined by the SSS. The study found
that the mean PUI value tended to be higher in MS patients than controls but this did not
reach significance. Unexpectedly they found a significant inverse correlation in MS
patients between PUI and fatigue as determined by the FSS and MFIS. This would seem
to suggest that fatigue in MS patients was associated with higher levels of alertness which
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seems at odds with what would be expected. The investigators, however, preferred to
conclude that autonomic instability was not associated with fatigue in MS.
A further study by the same group involved 61 MS patients and 42
controls[79]. This again included a number of patients with a single attack or undergoing
a relapse. Patients underwent the PST as well as completed the ESS and SSS. No fatigue
assessment was performed as the investigators were primarily evaluating
hypersomnolence in MS. No difference was found between patients and healthy
volunteers in terms of the PUI and the questionnaire-based measures. It was noted that,
after correction for age and sex, there was a significantly smaller mean pupil diameter in
the MS group. No correlation was found between the pm and ESS or SSS scores. It is of
note that there were a higher number of healthy volunteers (38%), as compared to the MS
cohort (26%), with an ESS score indicative of EDS, although this was not statistically
significant. It was concluded that there was no pupillographic evidence ofEDS in MS.
1.9 EDS and fatigue in bypenomnolent conditions
The idea of an association between fatigue and sleepiness is contentious. Some authors
feel it is clear that somnolent patients suffer with fatigue. Others however disagree and
maintain that fatigue is a common, non-specific complaint that should be differentiated
from sleepiness and may be more likely to signify depression.
Evidence does exist however to support the former argument that fatigue is
a component of hypersomnolent conditions. OSAHS, a condition characterised by brief
episodes of asphyxia during sleep with associated oxygen desaturation secondary to
obstruction of the pharynx, is classically associated with EDS. However, a study of 190
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patients with OSAHS revealed that reports of fatigue, lack of energy and tiredness were
more frequent than sleepiness[80]. In fact lack of energy was considered by the group as
the major problem they faced.
Narcolepsy is the classical hypersomnia disorder and will be discussed in
more detail later. Patients with narcolepsy in one study complained of significantly
greater fatigue than controls[81]. In addition, narcoleptics report significantly low levels
of energy and vitality on quality of life questionnaires[82]. Modafinil, a wake-promoting
drug, is commonly used as first choice treatment for narcolepsy in the United Kingdom.
Trials of the use of modaflnil for EDS in narcolepsy patients have also shown a
significant improvement in vitality scores[83, 84].
1.10 Nareolepsy
Narcolepsy is a condition first described by Westphal in 1877 and is characterized by a
tetrad of clinical features. EDS is the principal symptom. It is constant although will
fluctuate in severity and improve after a nap. Cataplexy is the term for episodic bilateral
loss of striated muscle tone provoked by emotion, most typically laughter. As with EDS
the threshold for provoking these attacks varies. The third feature is hypnagogic
hallucinations which are vivid, dream-like episodes occurring at the onset of sleep. They
are short-lived, typically frightening, visual experiences sometimes with auditory and
tactile elements. Finally, sleep paralysis which is the sensation of complete or partial
inability to move either at the onset of sleep or awakening. They are also typically
frightening and may be associated with the hallucinations.
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Other symptoms such as disturbed nocturnal sleep with brief frequent
awakenings and automatic behaviour, whereby brief, semi-purposeful activity whilst
drowsy and of which the patient is amnestic, are also frequently seen in narcoleptics.
1.10.1 Pathophysiologyof narcolepsy
The majority of cases of narcolepsy are sporadic whilst 1% are familial with a typically
autosomal dominant pattern of inheritance. Genetic factors do however play a role in
sporadic cases. The clearest example of this is the association with a specific Hl.A
subtype on chromosome 6. There is a strong association between narcolepsy and Hl.A
DQB 1*0602 and the risk for developing narcolepsy is even higher in patients who are
homozygous for this DNA subtype.
Traditionally all diseases associated with specific Hl.A subtypes are
autoimmune diseases. Therefore the hypothesis considered most probable is that of an
autoimmune process affecting an area of the brain central to sleep regulation and leading
to narcolepsy. There has, however, been little laboratory evidence to support this. Studies
have shown no cerebrospinal fluid (CSF) abnormalities such as oligoclonal bands or
abnormal cell counts although a recent study did suggest the presence of an IgG
autoantibody in the serum ofnarcoleptics[85, 86].
1.10.2 Bypocretin and the hypothalamus
In 1998, two independent groups described two hypothalamic, excitatory neuropeptides
that each named either bypocretin-l and -2 or orexin-A and -B[87, 88]. It soon became
clear that these separately-termed peptides were one and the same.
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In humans, hypocretin-containing neurons are localized in the posterior
and lateral hypothalamic nuclei but project widely throughout the brain and spinal cord.
Their dendrites secret hypocretin-l and -2 that interact with two hypocretin receptors
(hcrtr-l and -2). These receptors are spread widely including the cerebral cortex,
amygdala, hippocampus, thalamic and subthalamic nuclei as well as brainstem structures,
including the reticular formation, dorsal raphe nuclei and LC.
Hypocretin is felt to have a number of important roles including energy
metabolism, autonomic function and may activate the HPA axis. However, it became
apparent in the late 1990s that hypocretin played a key role in the development of
narcolepsy.
Canine narcolepsy was detected in a number of breeds in the 1970s. In
1999 it was identified that mutations in hcrtr-2 gene and subsequent reduction in the
function of hcrtr-2 led to familial canine narcolepsy but without alteration in the number
of hypocretin neurons or reduction in the CSF hypocretin-l levels. Sporadic canine
narcolepsy, on the other hand, does involve loss of hypocretin neurons and consequently
low CSF hypocretin-l levels. A murine narcolepsy model was also developed with
hypocretin knockout mice lacking both hypocretin-l and -2[89].
Evidence for the role of hypocretin in human narcolepsy followed on. An
early study found that CSF hypocretin-l levels were undetectable in seven of nine
narcoleptics investigated[90]. Hypocretin-l and -2 have been found to be absent in brain
tissue (cortex and pons) of six narcoleptics in a separate study[91]. In the same study,
hypocretin mRNA was absent in sections of hypothalamus of two narcoleptics whilst a
different hypothalamic peptide mRNA was intact. A further study showed a marked
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reduction of 85-95% in the number of hypocretin-containing neurons in the hypothalamic
tissue of four narcoleptics[92]. There was also some suggestion of neurodegeneration
with an increase in the number of astrocytes in the hypothalamus. It is therefore
postulated that the hypocretin neurons are reduced due to some autoimmune process.
Quantitative MRI has been employed to investigate further. Lodi et al used
IH_MRS in 23 narcoleptics[93]. They applied a volume of interest to include bilateral
hypothalami and evaluated for reduction in NAA. The study found a significant reduction
in NAA content in narcoleptics as compared to controls. In addition, NAA content was
lower in narcoleptics with cataplexy than those without. Other than the presence of
cataplexy there was no relationship between the IH-MRS results and PSG or MSLT
results. A separate study applied IH-MRS to the brain stem (the ponto-medullary junction)
ofnarcoleptics and found no difference between patient and control groups[94].
Another group used an alternative quantitative MRI technique, voxel-
based morphometry, to assess the cortical and sub-cortical grey matter including specific
regions of interest such as the lateral hypothalamus and amygdala in 12 narcoleptics with
cataplexy[95]. This study found a significant reduction in cortical grey matter volume in
narcoleptic patients as compared to controls. This reduction was mainly in the inferior-
temporal and frontal regions. Sub-cortical structures including the hypothalamus did not
show any significant difference as compared to controls.
1.11 Hypocretin and nartolepsy symptomatology
The mechanism of how hypocretin deficiency leads to narcolepsy is uncertain.
Hypocretin neurons are most active during wakefulness and less active in non-REM
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sleep. Inhibition of hypocretin neurons seems crucial for sleep initiation. A study has
shown that local administration of hypocretin-l into the Le suppressed REM sleep in a
dose-dependent fashion. In addition, an antibody that neutralizes hypocretin could block
this suppression of REM sleep.
Hypocretin neurons interact with a spectrum of neurotransmitters for
example cholinergic cells in the basal forebrain and dopaminergic cells in the brainstem.
It is postulated that hypocretin neurons act as a stabilizer between maintenance of
wakefulness and promotion of sleep. Subsequently it is felt that narcolepsy symptoms are
most likely secondary to neurotransmitter imbalance due to an altered signal from
hypocretin-containing neurons.
EDS is felt to be secondary to reduced dopaminergic transmission.
Hallucinations are a manifestation of REM sleep in drowsiness whilst cataplexy and sleep
paralysis are manifestations of REM sleep during wakening with REM sleep
characterized by muscle atonia. Certainly muscle atonia is induced by activity of
cholinergic receptors and inhibition of motor neurons in the brainstem[89].
1.12 CSF bypoaetin-llevels and bypenomnia
Since the initial study, there have been a number of further studies evaluating the levels
of CSF hypocretin-l in a variety of hypersomnolent as well as inflammatory and
degenerative neurological conditions[96-I09].
A large study revealed 99010specificity and 87% sensitivity between low or
undetectable CSF levels and narcolepsy with cataplexy[96]. Normal levels were typically
associated with mild narcolepsy, atypical or no cataplexy, and even HLA DQB 1*0602 or
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DR2 negativity. In addition, studies have shown that undetectable CSF hypocretin-l
levels were significantly associated with shorter latency to sleep onset and a higher
frequency ofSOREMPs on MSLT and therefore associated with more severe EDS[97].
One study reported that 25% of patients with idiopathic hypersomnia have
moderately low CSF hypocretin-l levels[98]. A single patient (3% of cohort) with
OSAHS in a further study was also found to have a low level[96].
Case reports also reveal low CSF hypocretin-l levels in a variety of
secondary hypersomnia conditions. A patient developed narcolepsy with cataplexy, with
a moderately low hypocretin-l level, presumed to be as a consequence of the
diencephalic stroke he sustained post-surgical removal of a craniopbaryngioma[99]. Low
hypocretin-l has also been reported in other cases including hypothalamic tumours and
Prader-Willi syndrome(lOO, 101].
A number of groups have also looked at other neurological conditions.
Studies have looked at groups of patients suffering from Guillain-Barre Syndrome (GBS)
in the context of this being an immune-mediated condition. These found that between 18
- 64% of patients have low or undetectable levels, with a higher percentage of patients
being affected in the Japanese cohorts[I02-104]. There is some suggestion that low levels
may be associated with rapidly progressive GBS[I03]. Patients with Miller-Fisher
Syndrome, a variant of GBS, also had a low hypocretin-l level in 42% of cases[103].
Another study revealed low CSF hypocretin-l levels in a small group of patients with
SLE[105].
Investigators have also looked at patients with conditions where EDS or
sleep-wake disorders are common complaints. A study of six patients with myotonic
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dystrophy who suffered from EDS concluded that a single patient had a CSF level within
the narcolepsy range whilst three further patients had moderately low levels[ 106]. The
levels did not correlate with disease severity, ESS score or MSLT severity. One group
looked at a cohort of 19 patients with advanced Parkinson's disease and found
undetectable levels in nine and moderately low levels in ten patients[I07]. Levels did
correlate with disease severity but not ESS score. A smaller study, however, revealed
normal levels in each of three Parkinson's disease patients who complained ofEDS[108].
Baumann et al investigated 44 patients who had suffered traumatic brain injury (TBI) and
reported low or undetectable levels in 37 patients with moderate-severe TBI but not in
those with mild TBI[I09].
1.13 CSF bypocretin-llevels in CNSdemyelinatingdiJorden
There are certainly a number of case reports of patients with MS who develop
hypersomnia as their manifestation of a relapse. A 22-year old woman with MS
developed acute hypersomnia and was found to have new bilateral-hypothalamic lesions
on MRJ[IlO]. Her CSF hypocretin-I level was undetectable. Similarly a 45-year old
woman, again with a history of MS, developed hypersomnia and was also found to have
bilateral hypothalamic lesions on MR.I[I I I]. CSF Hypocretin-I level was undetectable.
Neither case reported other features of narcolepsy. Interestingly the latter case reports the
fact that prior to her relapse and whilst asymptomatic, in terms of somnolence, she was
found to have a new lesion only in the right hypothalamus. This may be consistent with
the human neuro-pathological studies, whereby patients showed an 85 - 95% reduction in
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hypocretin-containing neurons in narcolepsy[92]. Is there a point, in terms of loss or
dysfunction of hypocretin-containing neurons, at which patients become symptomatic?
Gledhill et at report a case of secondary narcolepsy without cataplexy in a
patient with acute disseminated encephalomyelitis (ADEM)[112]. ADEM is a para-
infectious or post-vaccination monophasic CNS demyelinating disorder presenting
typically with a degree of encephalopathy and multifocal neurological signs. The patient
presented with acute hypersomnia, disorientation and brainstem signs. MRI imaging
revealed lesions involving, amongst other areas, the hypothalami and CSF analysis
revealed a low hypocretin-l level.
A number of studies have investigated hypocretin-l levels in cohorts of
MS patients without specifically looking at EDS. Kanbayashi et al obtained CSF from
eight MS patients amongst a larger study involving patients with inflammatory
(predominantly GBS) and non-inflammatory (parkinson's disease, stroke, epilepsy,
dementia) neurological disorders[102]. Although patients with GBS had significantly
lower hypocretin-l levels than patients with non-inflammatory disorders, MS patients did
not. MS patient's CSF hypocretin-Ilevels were within normal range.
A further study looked at 44 patients with MS, again within the context of
a larger study of patients with a wide variety of neurological as well as psychiatric
disorders[I05]. These included; infective CNS diseases, benign intracranial hypertension,
normal-pressure hydrocephalus and conversion disorders. The MS patients' results were
within control range however it was noted that low levels were present in some patients
in all of the groups.
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A study by Knudsen et al investigated 23 MS patients and 25 patients with
optic neuritis[ 113]. It was noted that the majority of patients in each group were
undergoing an acute attack and the specific aim was to compare patients in remission
from those in an acute phase. They found normal CSF hypocretin-l levels in all patients
with no difference between the attack and remission groups. Thirty-six patients also
completed the ESS with five patients having scores indicative ofEDS. No analysis was
reported on whether hypocretin levels were different in patients with hypersomnolence
nor any correlation analysis ofESS scores and CSF levels.
1.14 EDS in MS
As reported above, hypersomnia can occur in MS patients as a symptom of an acute MS
relapse. Studies also show that MS patients who suffer from fatigue may also complain of
EDS. One small study involving 30 MS patients revealed that 60010of those with MS-
related fatigue had hypersomnia as determined by the ESS. This compared to 13% of
those without fatigue[ 114].
Furthermore studies have investigated the complaint of EDS in patients
with MS-related fatigue by looking at whether sleep disturbance or circadian rhythm
disorders may contribute to either of these complaints. Conflicting results have emerged.
Taphoorn et al employed actigraphy and MSLT in a study of 16 MS patients with fatigue.
Actigraphy involves a wrist-worn motion-detector that can monitor and store activity
during sleep and wake for prolonged periods[115]. It is able to detect sleep disturbances
and circadian rhythm disorders. The investigators found no evidence of a circadian
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rhythm disorder in MS patients and no difference in actigraphy between patients and
controls.
A further small study evaluated six MS patients with fatigue, but without
EDS as measured by the ESS and MSLT, for circadian rhythm disorder by using body
core temperature and PSG[116]. The investigations revealed normal sleep-wake rhythm
and sleep structure.
On the other hand, Attarian et al compared 15 patients with and 15 patients
without MS-related fatigue again using actigraphy as well as the ESS and fatigue
questionnaires[114]. Two patients from the fatigue group had a circadian rhythm
abnormality and a further 10 had disrupted sleep. This study found a significantly high
probability of a relationship between the presence of fatigue and abnormal sleep cycle or
disturbed sleep.
1.15 Treatment of bypenomnolenee in narcolepsy
Lifestyle changes are of value in the management of narcolepsy, such as planned daytime
naps and avoiding large carbohydrate meals and alcohol consumption. However,
pharmacological treatment is the mainstay with eNS stimulants having been the
traditional approach. These include methamphetamine, dextroamphetamine,
methylphenidate and pemoline. Side effects such as tachycardia, irritability, agitation and
headache as well as tolerance and the potential for abuse are significant drawbacks.
Modafinil is a non-stimulant, wake-promoting drug that has, over recent
years, become the most common, certainly in the UK, first-line agent introduced. It has
fewer side effects than stimulants and less risk of abuse.
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Modafinil was studied in a large multi-centre, double-blind, placebo-
controlled trial involving 240 narcoleptics who were randomized to one of two doses,
200mg or 400mg daily, or placebo[117]. After the nine-week study period, there was a
significant improvement with either dose in ESS scores as well as MWT and MSLT
mean sleep latency as compared to baseline. There was a significant improvement in
MSLT mean sleep latency in the larger dose cohort as compared to placebo. Both
treatment groups showed a significant improvement compared to placebo in ESS scores
and MWT mean sleep latency.
Its mode-of-action is unclear. It is hypothesized that it likely interacts with
a complex network within the hypothalamus and brainstem. A number of wakefulness-
promoting neurons have been identified including; the hypocretin-containing neurons of
the posterior and lateral (perifornica1) hypothalamus; the histamine-containing neurons of
the tuberomamillary nucleus (TMN) in the posterior hypothalamus; the noradrenergic
neurons of the Le in the pons and dopaminergic neurons within the ventral tegmental
area of the midbrain. Potential sleep-promoting neurons include the GABA-ergic neurons
of the ventrolateral preoptic nucleus (VLPO) of the hypothalamus. Interconnection
between these cell groups is thought to fonn an arousal system which itself projects
widely through the cerebral cortex.
In animal studies, modafinil has been shown to activate a number of these
areas. Scammell et al conducted a study that involved assessing the expression of the
transcription factor Fos (this being an indicator of neuronal activation) in the brain after
administering modafinil[118]. Firstly, it was noted that modafinil promoted wakefulness
in the rats. In addition, there was evidence of increased neuronal activation with
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modafinil, as compared to a control substance, in hypothalamic areas, namely the TMN
and the perifomical area. Other areas including the LC also showed significant activation.
With double immunohistochemistry staining, it was also shown that it was indeed
hypocretin-containing neurons activated by modafinil in the perifornical area. When
modatinil was infused during what would be the normal sleeping period, it was also
demonstrated that there was a significant decrease in activation within the VLPO as
compared to the control substance.
Furthermore, in human studies some evidence has also been provided for
the activation of the LC by modafinil. Modaflnil showed an apparent opposite effect on
alertness and autonomic testing to the drug clonidine in healthy controls[119]. The LC is
particularly sensitive to the effects of clonidine with so-called switching-off occurring.
Therefore modatinil has been shown to activate wake-promoting neurons and suppress
sleep promoting neurons' activity but it is not clear whether this is through a direct or
indirect mechanism on these centres.
1.16 Management of MS-fatigue
Obviously treatment of any factor leading to secondary fatigue is essential. For example,
neuropathic analgesia or anti-spasticity agents in patients with disturbed sleep due to pain
or spasms. Appropriate management of depression is also essential in view of its role as a
potential confounding factor in MS-related fatigue. Further specific interventions for
primary MS fatigue will now be detailed.
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1.16.1 Non-pharmacologicalmanagement
A number of approaches have been proposed and investigated for MS-fatigue. Energy
conservation courses are often employed by occupational therapists and a study by
Mathiowetz et a1 has supported its role. A six-session, two-hour per week course was
shown to significantly improve fatigue scores in a group of 54 MS patients[120]. Quality-
of-life scores also improved including vitality subscales. Energy conservation methods
commonly employed include; addressing the importance of rest periods; ergonomic
principles regarding one's own body, as well as the work or home environment; priority
setting; recognizing personal limits and living a balanced lifestyle.
Exercise programs are another method employed by therapists to improve
MS-related fatigue with studies having confirmed its value. One such study looked at a
six-month period of weekly yoga classes or weekly aerobic exercise with a stationary
bicycle or no active intervention[ 121]. There was a significant improvement with either
treatment in both fatigue measures and again quality-of-life vitality scores. A shorter-
term exercise program of only 12-weeks duration, as part of a multi-disciplinary, holistic,
outpatient rehabilitation program, again showed a significant improvement in fatigue,
quality oflife and also depression[122].
Cooling garments or cooling water baths are often advised to fatigue
sufferers in view of the clear association of increased MS-fatigue with higher body
temperatures.
1.16.2 Phannacological treatment
A number of agents have been evaluated and employed for MS-related fatigue.
60
1.16.3 Amantadine
Amantadine was introduced as an anti-viral agent before then finding a role in the
management of Parkinson's disease, particularly the treatment of motor dyskinesias. Its
mode of action in Parkinson's is likely via its effect on glutamate receptors. Its mode of
action in fatigue is unknown.
Rosenberg and Appenzeller studied the effect of amantadine 200mg daily
for one week on fatigue in 10 MS patients in a randomized, double-blind, placebo-
controlled, crossover trial[123]. Six subjects reported a subjective improvement in fatigue
with amantadine as compared to one who felt an improvement with placebo.
Another study used a similar randomized, double-blind, placebo-
controlled, crossover design to evaluate the effect of four-weeks treatment with
amantadine 200mg daily in 29 patients[124]. Subjectively, there was a significant
improvement with amantadine, as compared to placebo, in a number of areas including;
energy level; concentration/memory function; overall well-being and ability to solve
problems, although not in an overall fatigue score. During treatment with amantadine
there was also a significant improvement in a task requiring sustained attention, the
Stroop Interference Test.
A double-blind, parallel group, six-week study was reported of 119 MS
patients randomized to amantadine 200mg daily, pemoline (building up to 56.2Smg daily)
or placebo[125]. Two subjective fatigue scales were used to evaluate response. The
amantadine group showed a significant improvement in fatigue as compared to placebo in
one scale, the MS-specific Fatigue Scale (MS-FS). There was however no significant
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difference in FSS scores between the groups although scores did improve compared to
baseline
Amantadine has subsequently received somewhat of an endorsement by
the National Institute for Clinical Excellence which suggested, whilst not to be used
routinely, patients should be informed ofa potential benefit for fatigue[126]. A Cochrane
Review, on the other hand, concluded that whilst generally well tolerated its efficacy is
poorly documented, with poor quality trials open to bias and only small and inconsistent
improvements in fatigue seen[127].
1.16.4 Pemoline
Pemoline is a CNS stimulant which was withdrawn from the UK in 1997 because of
concerns regarding hepatotoxicity although continued to be used in North America up to
2005. As well as the study described above, a second, randomized, double-blind, placebo-
controlled, crossover trial in 46 MS patients has been reported[128]. Four-weeks
treatment with an escalating dose of pemoline (up to 7Smg daily) was evaluated with a
visual analogue fatigue scale. No significant effect was seen although a trend for
improvement with pemoline was noted at the higher dosage.
1.16.5 AmiDopyridiDa
As mentioned earlier, there is a convincing association between fatigue and body
temperature and it is known that higher temperatures leads to increased intermittent
conduction block along demyelinated nerve fibres. Frequency-dependent conduction
block is one physiological mechanism for this intermittent conduction block. Partially
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demyelinated nerve fibres may conduct single or low frequency impulses faithfully but
are unable to transmit trains of impulses at high frequency. It has been therefore
hypothesized that fatigue may be a temporary weakness due to functional blockade of
conduction. In view of this, aminopyridines, as potassium channel blockers that prolong
the duration of the action potential and potentiate synaptic transmission, have been
studied as a potential treatment.
Studies of 3,4-diaminopyridine in small numbers of MS patients have
shown subjective improvements in fatigue as well as increased activation on fMRI[129].
In addition, an electrophysiological measure of fatigue during a simple maximal
voluntary isometric contraction also demonstrated a significant improvement with
treatment[130].
1.16.6 Moctarmil
Three studies have been undertaken to evaluate the potential effect of modafinil on MS-
related fatigue. Zitko et allooked at SOMS patients with chronic fatigue in an open-label,
non-placebo-controlled, two-centre study of modafinil, up to a maximum dose of 400mg
daily, for three months[131]. Tools used to evaluate response included the ESS and FSS.
Of note mean FSS score at baseline was 30.3 +/-8.5 indicating the group as a whole
suffered from severe fatigue. On the other hand, mean ESS score was 9.7 +/- 3.9
suggesting that hypersomnolence was not a significant problem for the group. There was
a significant improvement in both measures' scores with treatment (median daily dose
lOOmg).
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Rammohan et al conducted a nine-week, single-blind, cross-over study
involving 72 MS patients with severe fatigue as assessed by the FSS[132]. All patients
received placebo for weeks 1-2 and 7-9 and modafinil200mg for weeks 3-4, titrating to
400mg daily for weeks 5-6. Again FSS and ESS were used, amongst a number of other
measures. Although some patients did report hypersomnolence, as assessed by the ESS,
the mean ESS score at baseline was only 9.5 (range 1-20). There was a significant
improvement in FSS score with the lower dose as compared to placebo but not modafinil
400mg daily. Other subjective fatigue scales showed similar results. The ESS scores did,
however, significantly improve with both treatment doses as compared to placebo.
A five-week, double-blind, placebo-controlled, parallel-group study was
reported by Stankoff et al[133]. It involved 115 patients with chronic fatigue randomized
to modaflnil titrating up to 400mg or placebo. The MFIS (primary outcome), a fatigue
visual analogue scale and the ESS were employed in the study. There was no significant
difference in any of the measurements with modafinil as compared to placebo.
1.17 Summary and aim.
Fatigue is a common and major symptom in MS. A number of potential mechanisms have
been proposed as to its pathogenesis. The preceding review has illustrated the
involvement of deep grey matter structures in several of these models. One of the primary
aims of this thesis was to investigate any association between deep grey matter pathology
and MS-fatigue.
Conventional MRI techniques are an important tool in the diagnosis of MS
and monitoring disease activity. However, it is evident that quantitative MRI techniques
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can demonstrate abnormalities in normal appearing tissue thereby providing a more
comprehensive picture of the disease burden. It is felt that these non-conventional
measures hold significant promise in offering a better correlation with clinical features.
TI mapping is one such technique and has previously demonstrated
pathology in small structures such as the pyramidal tracts and a correlation with
disability. To this end, we employed TI mapping in the thalamus and basal ganglia to
investigate the potential role of disruption of cortico-subcortical circuits in contributing to
MS-fatigue.
Conventional MRI techniques have identified lesions occurring in the
hypothalamus but quantitative MRI has not been previously employed to assess this deep
grey matter structure in MS[IIO, Ill]. As described in this introduction, it is implicated
in MS-fatigue through its role in the autonomic and neuroendocrine system as well as the
hypocretin pathway. To further evaluate this we performed Tl mapping on the
hypothalamus, measured CSF hypocretin-l levels in a further cohort of patients as well as
undertook autonomic investigations.
Management ofMS-fatigue requires a multi-disciplinary approach as well
as pharmacological agents. Studies on the efficacy of treatments for fatigue are
complicated by the difficulty in defining fatigue and the reliance on determining response
with subjective questionnaires. The wakefulness-promoting agent, modafinil has been
assessed previously, in a limited number of studies, using these measures. Its likely
mode-of-action involves activation of a number of structures, including nuclei within the
hypothalamus and brainstem, which are components of the arousal system. The final aim
of this thesis is to further address the potential role for modafinil in MS-fatigue through
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the application of objective measures of alertness and vigilance to establish a more
accurate picture of its effect.
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CHAPTER2
Chapter 2. Tt RELAXATION TIMES OF THE DEEP GREY MATTER AND
FATIGUE IN MS
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1.1 Introduction
1.1.1 Tl relautioD time studiesinMS
Conventional MRI techniques, in particular T2-weighted imaging, have traditionally
focused on white matter abnormalities and have become the main paraclinical tool for
diagnosing MS. However, there is generally a poor correlation with clinical deficit and
disability. Tl relaxation time, or Tl mapping, is a quantitative MRI-derived measure and
has been used to demonstrate abnormalities in lesions and NAWM and provides better
correlation with clinical deficit. Studies have shown that, in MS lesions, T 1 relaxation
time correlates with degree of hypointensity and accordingly the Tl relaxation time of
hypointense lesions, on Tl-weighted images, has correlated significantly with
disability[134-136]. Tl relaxation time measurements are prolonged in the NAWM of
MS patients[135, 136]. Pathology within NAWM may correlate more strongly with
clinical status and progression in disability than T2 lesion volume[137, 138]. Studies
looking at the cervical spinal cord and the pyramidal tracts found significant correlations
between Tl relaxation times and disability measures[139, 140]. In NAWM, at least, it has
been suggested that Tl relaxation time measurement appears to be more sensitive than
MT, in detecting the subtle pathological abnormalities[l4].
2.1.2 Grey matter and Tl relaution time
T 1 relaxation times have been measured in both cortical and deep grey matter but with
diverse results. One investigation found significantly prolonged Tl relaxation time in the
frontal cortex in MS subjects[14]. However, another study showed no significant
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differences in cortical grey matter between patients and controls[ 141]. With regard to the
deep grey matter, a study looking at the thalamus found a significantly prolonged Tl
relaxation time in secondary progressive MS (SPMS) patients, as compared to relapsing-
remitting MS (RRMS) or controls[136]. A further study found only an apparent trend for
higher Tl values in the deep grey matter, whilst no significant difference was found in a
third study[ 14, 141].
2.1~ ~s
Therefore to explore further the possible central component of fatigue in MS, we
measured the Tl relaxation time of deep grey matter structures in a cohort of RRMS
patients. The specific aims of this study were: (i) to assess any relationship between the
mean Tl relaxation times (Tl values) of the thalamus, putamen and caudate nucleus and
fatigue severity, (ii) to compare these Tl values with a group of age- and sex-matched
healthy volunteers, (iii) to evaluate any relationship between Tl values of the deep grey
matter structures and clinical features or T2 hyperintense lesion volume.
2.2 Materials and methods
2.2.1 Subjects
Fifty-two patients with RRMS as defined by McDonald's criteria were recruited[142,
143]. The group consisted of 12 males and 40 females with a median age of 39 years
(interquartile range [IQR], 32 - 43). Median disease duration was 9 years (IQR, 3 - 14)
and the median Expanded Disability Status Scale (EDSS) score was 2.S (IQR, 2 -
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3.5)[144]. All subjects were relapse- and corticosteroid-free for at least one month. Eight
patients had been receiving glatiramer acetate treatment for approximately six years. No
patients suffered from significant medical or psychiatric conditions that could confound
the study.
The normal control cohort consisted of 19 subjects (5 male and 14 female)
with a median age of 33 years (IQR, 28 - 40). The control and patient groups were
matched in terms of gender and age. The controls had no history of neurological disease
or other significant medical condition.
Approval was obtained from the Nottingham Research Ethics Committee.
All subjects gave informed consent.
2.2.2 Fatigue assessment
Fatigue was quantified using the FSS in 48 of the RRMS patients[23]. The FSS was
ascertained within twenty-four hours of the MRI and at the same time as the patients
underwent a full neurological examination by an experienced observer blinded to the scan
results. The 48 patients consisted of 11 males and 37 females; median age was 39 years
(IQR, 32 - 43), median disease duration 9 years (IQR, 3 - 14) and median EDSS 2.5
(IQR, 2-3).
For analysis relating fatigue severity to MRI and clinical parameters 14
patients, who were receiving medication that could potentially affect fatigue, were
excluded. The remaining sub-group of 34 patients consisted of 7 males and 27 females.
Their median age was 38 years (lQR, 32 - 42), median disease duration 9 years (IQR, 3 -
13) and median EDSS 2.S (IQR, 2 - 3). Two groups of MS patients were identified:
70
fatigued patients (F) (FSS score ~ 5.0 [n = 20]) and non-fatigued patients (NF) (FSS
score $ 4.0 [n = 11]). The three outstanding patients, with an FSS score of between 4.1
and 4.9, were not included in the F and NF group comparisons but their data was used in
correlation analyses.
1.1.3 MRIacquisition
All scans were performed on a 1.5 Tesla, Vision MR. scanner (Siemens Medical,
Erlangen, Germany). For the calculation of TI maps of the brain, image data was
obtained using a 3-D inversion recovery, fast low-angle shot (FLASH) sequence. The
sequence and method for calculation of the TI maps was performed as described in
previous studies by our group[139]. The following sequence parameters were applied:
echo time (TE) 3ms, flip angle 100, repetition time (TR) 4.8ms (per FLASH line), TR
5000ms (between inversion pulse) and 488Hz bandwidth per point. A 256 x 256 matrix
was used and twenty-four 3-D partitions were acquired with a voxel size of 1 x 1 x 3mm.
Seven inversion times were used ranging from 100 to 1800 ms. Total acquisition time
was 14 minutes.
PD- and T2-weighted images were obtained with a turbo spin echo
sequence with the following parameters: TR 4100ms, TE (PO) 22ms. TE (T2) 9Oms,
matrix 256 x 256, 46 interleaved 3mm axial slices.
1.1.4 MRIanllysis
All MRI analysis was performed on, in-house developed, software by an experienced
operator blinded to the subject's clinical details. Tl relaxation times were determined by
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defining regions of interest (ROIs) bilaterally, on axial Tl map slices, in three deep grey
matter areas: the thalamus, putamen and caudate nucleus. The ROIs were outlined on all
consecutive slices which demonstrated the structures. A semi-automated technique using
the Sobel operator and non-maximal suppression was employed (Fig 2.1)[145].
Briefly, the image intensity gradient is measured in the transverse plane for
each voxel by the Sobel operator. The gradient magnitude is highest for partially volumed
voxels. This allows for detection of the boundary between grey matter and CSF or white
matter. Therefore, the method does not depend directly on the voxel intensities but
requires a difference in intensity to delineate the edge. The boundary may be localized
precisely by eliminating all voxels except those where the gradient magnitude is maximal
in the direction of the gradient. This process of identifying the voxels is called non-
maximal suppression.
At some points, the boundary between grey and white matter was not
defined clearly. This occurred most frequently at the lateral edge of the thalamus.
Conservative manual correction of this was then required. The original Tl map images,
prior to the application of the Sobel operator and non-maximal suppression, were used as
reference images to help confirm the edges. To further avoid partial volume effects from
surrounding white matter and CSF, tissue the width of one voxel beneath the ROI outline
was also automatically removed from histogram analysis. Together this allowed for the
largest volume of the grey matter structures to be considered while avoiding
contamination. ROI histograms were then generated from the Tl map images.
Lesion volume was determined on T2-weighted images using a semi-
automated, seed growing technique. PD-weighted scans were used to confirm lesions.
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Figure 2.1 (A) TI image axial slice of a healthy volunteer after application of the
Sobel operator and non-maximal suppression to automatically detect the images. (B) the
same axial slice showing ROls defined by the detected edges and some manual editing
where necessary
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1.1.S Reproducibility
Intra-observer variation was determined by redefining the ROIs for all three deep grey
matter structures on 10, randomly-selected, patient's scans. These repeat measurements
were obtained a minimum of 4 weeks after the original set. The semi-automatic edge
detection method was again applied and histograms generated from the Tl maps.
1.2.6 Statistical analysis
The Mann-Whitney U-test was applied to compare the Tl values of the MS patient group
and the healthy controls. This was also used to perform comparisons between the F and
NF MS patient cohorts. Spearman's rank correlation coefficient (rho) was determined to
assess correlations between the clinical and MRI-derived parameters. A p value of less
than 0.05 was considered to be significant. Intra-observer error was expressed by the
coefficient of variation between the repeated measurements.
1.3 Results
1.3.1 Patients venul controls
The Tl values of the thalamus, putamen and caudate nucleus are reported in Table 2.1
and Fig 2.2. The median TI of the thalamus and the putamen were significantly higher in
the MS patients than in the controls. In the caudate nucleus, the median T1 was also
higher in patients as compared to controls, however this did not reach statistical
significance. This result was also reproduced when examining only the subgroup of 34
patients not receiving medication that could potentially contribute to fatigue.
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2.3.2 Fatigued venus DOD-fatigued MS patieDts
Clinical parameters
The median FSS score of the F group was 6.1 (lQR 5.3 - 6.6) and of the NF group was
3.2 (IQR 2.7 - 3.6). Between the two groups there was no significant difference in age (F
39 years [IQR 31 - 43], NF 33 years [IQR 31 - 37]), sex (F 15% male, NF 18% male) or
disease duration (F 11 years [IQR 3 - 14], NF 7 years [IQR 2 - 12]). The F cohort had a
significantly higher median EDSS score (3.0 [IQR 2 - 4] vs. 2.0 [IQR 1.5 - 2.5]; P =
0.009).
T2 lesion load
Median T2 volume was not significantly different between the F 5.88 cm3 [IQR 2.87-
12.68] and NF 4.23 cm3 [IQR 1.98 - 7.44] groups.
T 1 relaxation times
The median Tl of the thalamus was significantly higher in the F group, as compared to
the NF (Table 2.2 and Fig 2.3). There was no difference between Tl of the putamen or
the caudate between the F and NF patients. This result was reproduced on including all
patients for whom FSS data was acquired.
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1.3.3 Fatigue correlations in RRMSpatients
Clinical parameters
Fatigue severity correlated significantly with EDSS score (rho = 0.S33;p = 0.001). There
was no significant correlation between fatigue severity and age (rho = 0.180;p = 0.31) or
disease duration (rho = 0.I63;p = 0.36).
12 lesion load
Fatigue severity did not correlate with T2 volume (rho = 0.I6I;p = 0.36).
T 1 relaxation times
The T 1 of the thalamus correlated significantly with fatigue severity (rho = 0.418; P =
0.014) (Fig 2.4). There was no significant correlation between fatigue and the Tl of the
caudate (rho = 0.276;p = 0.11) or the putamen (rho = 0.305;p = 0.079).
1.3.4 ConventionalMRI and diniw correlationsofTt relaution times
Age, disease duration, EDSS and T2 lesion volume did not correlate significantly with
the mean TI relaxation times of the individual deep grey matter structures.
1.3.5 Reproducibility
Intra-observer variability was 0.30010for the TI value of the caudate nucleus, 0.40% for
the putamen and 1.38% for the thalamus.
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Table 2.1 Deep grey matter T 1 values (ms) of patients and controls
Controls,
n= 19
RRMS,
n=52
pValue
Thalamus
Caudate
Putamen
927 (913 - 933) 942 (923 - 961)
1041 (1013 - 1074) 1054 (1042 - 1077)
952 (919 - 974) 969 (945 - 988)
0.012
0.066
0.027
Data are expressed as median (interquartile range)
RRMS = relapsing-remitting multiple sclerosis
Table 2.2
fatigue
Deep grey matter Tl values (ms) of RRMS patients with and without
Thalamus
Caudate
Putamen
F, n=20
956 (932 - 973)
1066 (1049 - 1092)
982 (963 - 1(00)
NF, n= 11
923 (893 - 949)
1057 (1050 -1067)
969 (938 - 984)
pValues
0.018
0.13
0.22
Data are expressed as median (interquartile range)
F = patients with fatigue; NF = patients without fatigue
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2.4 Discussion
In this study, we measured Tl relaxation time in three deep gray matter structures. This
quantitative parameter has been used previously to investigate MRI detectable changes in
MS but, in common with other quantitative parameters, has shown varying sensitivity to
the changes in the deep gray matter of RRMS patients. Previous studies applied small
ROIs of various sizes, with areas of between 10 and 36 mnr', centrally to each
structure[14, 136, 141]. This can limit sample size and result in large variance on the
mean T1 value. A potential limitation of our technique was the possibility of increased
influence from partial volume effects. By employing an edge detection method and
discounting the voxel directly beneath the edge we are confident the risk was minimized.
Furthermore, we used a 3D acquisition to reduce image artifact. Our technique also
showed a high level of reproducibility.
2.4.1 Tl relaotion times in patients and controls
Prolongation of Tl relaxation times has been shown to be due to gliosis or expansion of
the extracellular space, which itself can be secondary to vasogenic oedema or axonal
loss[ 146, 147]. Higher T1 values correlate with increasing degrees of hypointensity of
MS lesions on Tl weighted images that in tum, histopathologically, have been associated
with more severe axonal loss[ 148]. Studies also found that, in MS lesions, degree of
hypointensity and increasing Tl relaxation time were highly correlated with reduction of
the MTR[134]. Reduced MTR, in turn, correlates with higher degrees of axonal loss in
postmortem samples[14S]. In addition, IH_MRS of hypo intense lesions demonstrated that
reduction in NAA correlated strongly with prolongation of the Tl relaxation time[135].
SI
As discussed before, axonal loss may occur as part of MS lesions within the deep grey
matter structures[3, 6, 7], either due to the inflammatory activity or possibly the loss of
trophic support[ 5]. Axonal loss may also be secondary to degeneration anterograde to a
focal lesion outside of the grey matter. This pattern of Wallerian degeneration has been
described in demyelinating conditions[149, ISO]. Our study, notably, found no
correlation between the deep grey matter TI values and the T2lesion volume.
Our study demonstrated significantly longer TI relaxation times of two
deep gray matter structures, the thalamus and the putamen, in RRMS patients when
compared to healthy volunteers. This is, to our knowledge, the first report of such a
finding. A third structure, the caudate nucleus, also showed a longer TI relaxation time in
RRMS patients but did not reach statistical significance. Prolonged TI relaxation time
was previously reported in the thalamus of SPMS patients when compared with an
RRMS group or healthy controls[136]. However, there was no significant difference
between RRMS patients and the control group. A cohort of both RR- and SPMS patients
was also used in another study, which found no significant difference with healthy
controls[ 141]. Griffin et al investigated a group of RRMS patients and found only an
apparent trend for higher Tl values in the deep grey matter[l4]. Their research, however,
was into early disease with a symptom duration of less than 3 years and mild disability,
with an EDSS score of less than or equal to three. This would suggest that the pathology
that leads to prolongation of the Tl relaxation time, in the deep grey matter of RRMS
patients, is either a gradual process or simply a later phenomenon. Contrary to this notion,
however, we found that the duration of symptoms did not correlate with the Tl values of
the deep grey matter.
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2.4.2 MS-related fatigue - dinical correlations
Our results reveal a correlation between fatigue severity and disability, which
interestingly was despite a relatively low median EDSS score for the patient cohort.
Earlier studies have also shown a correlation between fatigue and disability[151). In
addition, a study, which involved SPMS as well as RRMS patients, found a higher
frequency of SPMS in the fatigued group that would suggest that as disability increases
fatigue becomes a more frequent complaint[52]. This is, however, not a consistent finding
with a number of investigations showing no association between FSS and EDSS
scores[17, 21]. Disease duration has not been shown to be associated with fatigue severity
and it is known that fatigue can be the first symptom of MS[ 17, 21, 52]. Our results also
show no correlation between fatigue and disease duration.
2.4.3 MS-related fatigue - MRI correlations
In agreement with most published studies we found no correlation between T2 lesion
volume and fatigue severity. This has been discussed in detail within the introduction.
Our results, therefore, support the premise that abnonnalities on conventional MRI have a
limited, if any, role to play in the pathophysiology offatigue.
Our study demonstrated that fatigue severity correlates with the T 1 value
of the thalamus, with a significantly higher Tl value of the thalamus in RRMS patients
with fatigue as compared to those without. First of all this supports the concept that it is
the spatial distribution of pathology in MS that is most relevant in terms of clinical
features rather than the overall disease burden. Moreover, it may be that non-
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conventional MRI techniques are necessary to provide solutions to the clinical-
radiological paradox. In addition, it supports previous studies discussed in chapter 1,
which have appeared to imply a role for the deep grey matter structures in the
pathophysiology ofMS-related fatigue.
An tMRI study found that, during a simple motor task, RRMS patients
with fatigue showed significantly lower, relative activation of the thalamus as well as
certain cortical areas including the rolandic operculum and the middle frontal gyrus[58].
A significant inverse correlation between fatigue severity and the activity in the
contralateral thalamus and ipsilateral rolandic operculum was found. In addition, a PET
study revealed reductions in CMRGlu in MS patients with severe fatigue, as compared to
those without fatigue, in several areas including the prefrontal cortex, premotor cortex
and supplementary motor area as well as the putamen and head of the caudate
nucleus[17]. These areas are important in a number of tasks including motor
programming and execution. The purported mechanism is the disruption of cortico-
subcortical circuits linking cortical grey matter with the basal ganglia and thalamus. It is
suggested that this dysfunction may lead to over-activity in alternative pathways to
enable motor programming and it is this compensatory mechanism that contributes to
fatigue. Our findings provide additional support for this hypothesis.
To summarise, this study found evidence of abnormal TI relaxation times
of the thalamus and putamen in RRMS. This supports previous studies that have
demonstrated pathology within deep grey matter structures. Furthermore, this pathology
within the thalamus was associated with fatigue severity and provides evidence for a role,
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potentially through dysfunction of cortico-subcortical circuits, in the pathophysiology of
MS-fatigue.
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CHAPTER3
Cbapter 3. Tt RELAXATION TIME MAPPING OF THE HYPOTHALAMUS
AND FATIGUE IN MS
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3.1 Introduction
3.1.1 Tl relaxation time studies inMS
As discussed in the previous chapter, T 1 relaxation time is a quantitative MRI -derived
measure and has been used to demonstrate abnormalities in MS lesions, NAWM and grey
matter and has been shown to correlate better with clinical deficit. It is sensitive in
detecting subtle pathological abnormalities. It has also been used in the preceding chapter
and in previous studies in small structures such as the basal ganglia, thalamus and
cervical spinal cord.
3.1.2 Hypothalamusod MS
Although not considered a typical site of involvement in MS, post mortem studies have
previously shown the presence of both plaques and axonal damage in and around the
hypothalamus[3, 6]. Evidence of involvement on MRI has been predominantly limited to
case reports often of individual patients who have presented with symptoms suggestive of
hypothalamic involvement[110, 11I, 152]. There is a single quantitative MRI study
which has demonstrated focal atropby in, amongst a number of areas, the hypothalamus,
in patients with a clinically isolated syndrome (CIS) and at risk of developing MS[153].
There are also a number of studies that have evaluated groups of patients with a
combination of conventional MRI techniques and neuroendocrine investigations[43, 154,
ISS). These have demonstrated neuroendocrine abnormalities although the results have
varied between similar studies.
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3.1.3 Hypothalamusand fatigue
A number of eNS mechanisms potentially involved in the pathophysiology of fatigue,
including autonomic and neuroendocrine dysfunction, have been described in the
introduction. There is a potential role for the hypothalamus in a number of these
mechanisms due to its significant interconnections and its involvement in key
homeostatic mechanisms. Descending autonomic neurons originate from hypothalamic
nuclei including the para ventricular nuclei synapsing with preganglionic sympathetic and
parasympathetic neurons. Emotional control on the autonomic system is thought to be
mediated by hypothalamic-limbic pathways. Some of these limbic pathways, such as the
mamillothalamic tract, pass via thalamic nuclei. Neurons from the supraoptic and
paraventricular nuclei project to the posterior pituitary stimulating the secretion of
oxytocin and vasopressin (VP). Additional neurons from other hypothalamic nuclei
project to the median eminence of the infundibulum with activation leading to the release
of peptides which in turn leads to hormone release from the anterior pituitary. In addition
the potential factor of hypersomnolence inMS-fatigue also implicates the hypothalamic-
hypocretin neurons.
3.1.4 J\ims
Therefore to explore further the possible central component of fatigue in MS, we
measured the Tl relaxation time of the hypothalamus in a cohort ofRRMS patients. The
specific aims of this study were: (i) to assess any relationship between the mean T 1
relaxation time (11 value) of the hypothalamus and fatigue severity, (ii) to compare the
Tl value with a group of age-matched healthy volunteers, (iii) to evaluate any
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relationship between Tl values of the hypothalamus and clinical features or T2
hyperintense lesion volume.
3.2 Materials aDdmethods
3.2.1 Subjeds
Thirty-eight patients with RRMS as defined by McDonald's criteria were recruited[142,
143]. The group consisted of9 males and 29 females with a median age of38 years (IQR,
32 - 41). Median disease duration was 9 years (IQR, 3 -13) and the median EDSS score
was 2.5 (IQR, 2 - 3)[144]. All subjects were relapse- and corticosteroid-free for at least
one month. Seven patients had been receiving glatiramer acetate treatment for
approximately six years. No patients suffered from significant medical or psychiatric
conditions that could confound the study.
The normal control cohort consisted of 13 subjects (5 male and 8 female)
with a median age of 35 years (IQR, 29 - 42). The control and patient groups were
matched in terms of age. The controls had no history of neurological disease or other
significant medical condition.
Approval was obtained from the Nottingham Research Ethics Committee.
All subjects gave informed consent.
3.2.2 Fatigue assessmeDt
Fatigue was quantified using the FSS in the patient group[23]. The FSS was ascertained
within twenty-four hours of the MRI and at the same time as the patients underwent a full
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neurological examination by an experienced observer blinded to the scan results. For
analysis relating fatigue severity to MRI and clinical parameters 11 patients, who were
receiving medication that could potentially affect fatigue, were excluded. The remaining
sub-group of 27 patients consisted of 6 males and 21 females. Their median age was 36
years (IQR, 31 - 41), median disease duration 10 years (IQ~ 3 - 13) and median EDSS
2.S (IQ~ 2 - 3). Two groups ofMS patients were identified: fatigued patients (F) (FSS
score ~ S.O[n = 17]) and non-fatigued patients (NF) (FSS score $ 4.0 [n = 8]). The two
outstanding patients, with a FSS score of between 4.1 and 4.9, were not included in the F
and NF group comparisons but their data -, used in correlation analyses.
3.2.3 MRI acquisition
All scans were performed on a 1.5 Tesla, Vision MR scanner (Siemens Medical,
Erlangen, Germany). For the calculation of Tl maps of the brain, image data was
obtained using a 3-D inversion recovery, fast low-angle shot (FLASH) sequence. The
sequence and method for calculation of the TI maps was performed as previously
described[139]. The following sequence parameters were applied: echo time (TE) 3ms,
flip angle 100, repetition time (TR) 4.8ms (per FLASH line), TR SOOOms(between
inversion pulse) and 488Hz bandwidth per point. A 256 x 256 matrix was used and
twenty-four 3-D partitions were acquired with a voxel size of 1 x 1 x 3mm. Seven
inversion times were used ranging from 100 to 1800 ms. Total acquisition time was 14
minutes.
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PD- and T2-weighted images were obtained with a turbo spin echo
sequence with the following parameters: TR 4100ms, TE (PD) 22ms, TE (T2) OOms,
matrix 256 x 256, 46 interleaved 3mm axial slices.
3.2.4 MRI analysis
All MRI analysis was performed on in-house developed software by an experienced
operator blinded to the subject's clinical details. Tl relaxation times were determined by
defining ROJs bilaterally, on axial Tl map slices, in the hypothalamus. The ROIs were
outlined on all consecutive slices which demonstrated the structures. A semi-automated
technique using the Sobel operator and non-maximal suppression was employed as
described in chapter 2(Fig 3.1)[145].
The medial aspect of the hypothalamus borders CSF, however at a number
of points, the lateral boundary was not defined clearly. Conservative manual correction of
this was then required. The original TI map images, prior to the application of the Sobel
operator and non-maximal suppression, were used as reference images to help confirm
the edges. Similarly the rostral border of the hypothalamus had to be established and was
done so by identifying the anterior and posterior commissures which signifies the
superior margin of the nuclei. To further avoid partial volume effects from surrounding
white matter and CSF, tissue the width of one voxel beneath the ROJ outline was also
automatically removed from histogram analysis. Together this allowed for the largest
volume of the hypothalamus to be considered while avoiding contamination.ROJ
histograms were then generated from the TI map images.
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Figure 3.1 (A) Tl image axial slice of a healthy volunteer after application of the
Sobel operator and non-maximal suppression to automatically detect the images. (B) the
same axial slice showing ROIs defined by the detected edges and some manual editing
where necessary
92
3.2.5 Reproducibility
Intra-observer variation was determined by redefining the ROIs for the hypothalamus on
five, randomly-selected, patient's scans. These repeat measurements were obtained a
minimum of four weeks after the original set. The semi-automatic edge detection method
was again applied and histograms generated from the Tt maps.
3.2.6 Statisticalanalysis
The Mann-Whitney U-test was applied to compare the Tl values of the MS patient group
and the healthy controls. This was also used to perform comparisons between the F and
NF MS patient cohorts. Spearman's rank correlation coefficient (rho) was determined to
assess correlations between the clinical and MRI-derived parameters. A p value of less
than 0.05 was considered to be significant. Intra-observer error was expressed by the
coefficient of variation between the repeated measurements.
3.3 Results
3.3.1 Patients venul controls
The median T'l of the hypothalamus is significantly higher in the MS patients than in the
controls (Table 3.1 and Fig 3.2). This result was reproduced when examining the
subgroup of 27 patients not receiving medication that could potentially contribute to
fatigue (Fig 3.3).
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Table s.r Hypothalamus T1 values (ms) of patients and controls
Hypothalamus
Controls, RRMS,
1047(1028- 1080) 1114(1057- 1147)
p Value
0.001
n= 13 n=38
Hypothalamus
(sub-group)
1047(1028- 1080) 1120(1068- 1147)
n= 13 0=27
0.001
Data are expressed as median (interquartile range)
RRMS = relapsing-remitting multiple sclerosis
Tablel.2 Hypothalamic T1 values (ms) ofRRMS patients with and without fatigue
Hypothalamus
F,n=17 NF,n=8
1131(1068-1164) 1098(1070-1134)
pValues
0.288
Data are expressed as median (interquartile range)
F = patients with fatigue; NF = patients without fatigue
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3.3.2 Fatigued venus non-fatigued MS patients
Clinical parameters
The median FSS score of the F group was 6.2 (IQR 5.4 - 6.6) and of the NF group was
3.3 (IQR 2.8 - 3.8). Between the two groups there was no significant difference in age (F
39 years [IQR 31 - 42], NF 33 years [IQR 31 - 37]), sex (F 13% male, NF 12% male) or
disease duration (F 11 years [IQR 4 - 13], NF 8 years [IQR 2 - 13]). The F cohort had a
significantly higher median EDSS score (2.5 [IQR 2 - 4] vs. 2.0 [IQR 1.5 - 2.5]; P =
0.(03).
T2 lesion load
Median 12 volume was not significantly different between the F 5.93 cm3 [IQR 2.96-
15.66] and NF 3.54 cm3 [IQR 1.53 - 4.68] groups.
T I relaxation times
The median T 1 of the hypothalamus was not significantly different between the F 1131
ms [IQR 1068 - 1164] and NF 1098 ms [IQR 1070 - 1134] groups (Table 3.2 and Fig
3.4). This was reproduced on including all patients for whom FSS data was acquired.
3.3.3 Fatigue eorrelationl inRRMS patients
Clinical Parameters
Fatigue severity correlated significantly with EDSS score (rho = 0.683;p < 0.001). There
was no significant correlation between fatigue severity and age (rho = 0.091;p = 0.65) or
disease duration (rho = 0.029;p = 0.89).
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T2 lesion load
Fatigue severity did not correlate with T2 volume (rho = 0.302; P = 0.13).
T 1 relaxation times
There was no significant correlation between fatigue and the TI of the hypothalamus (rho
= 0.197;p = 0.32).
3.3.4 Conventional MRI and dinicai correlations of Tt relaxation times
T2 lesion volume did correlate significantly with the mean TI relaxation times of the
hypothalamus (rho = 0.617; P = 0.001). In addition, there was a significant correlation
between disease duration and Tl values (rho = 0.423; P = 0.028). Age and EDSS did not
correlate significantly with T 1 values.
3.3.5 Reproducibility
Intra-observer variability was 1.9D/ctfor the T 1 value of the hypothalamus.
3.4 Discu• • ion
In this study, we measured Tl relaxation time in the hypothalamus, a technique that has
not been previously applied to this structure in MS patients. As with the study of the
thalamus and basal ganglia, we aimed to measure the T1 value of the entire structure
employing an edge detection method and discounting the voxel directly beneath the edge
to minimize the risk of partial volume effects. The main challenges with investigating the
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hypothalamus with MRI are its small size and difficulty in detecting certain borders.
However, by applying an edge detection method that has been used before in assessing
both small and deep grey matter structures as well as good anatomical knowledge with
identification of markers such as the anterior and posterior commissures, artifact was
minimized whilst allowing for the maximum amount of hypothalamus to be included in
the analysis. Our technique showed a high level of reproducibility.
3.4.1 Tl relautioD times in patients and controls
This is to our knowledge the first study to employ a quantitative MRI technique to
investigate the hypothalamus in a cohort of MS patients. As discussed in the previous
chapters, more advanced MRI techniques are now readily used in MS studies to try and
answer what is commonly known as the clinical-radiological paradox. In previous studies
TI relaxation times have been measured in plaques, NAWM and grey matter.
Our study demonstrated significantly prolonged T1 relaxation time of the
hypothalamus in patients with RRMS as compared to age-matched controls. As discussed
in chapter 2, prolongation of TI relaxation times has been shown to be due to gliosis,
vasogenic oedema or axonal loss. Previous histopathological studies in MS have revealed
abnormalities in the hypothalamus.
Brownell and Hughes, in their pathological study of the distribution of
cerebral plaques in 22 unselected MS patients from the 1960s documented involvement,
albeit rare, of the hypothalamus[3]. Huitinga et al have reported the pathological findings
on 17 MS patients in a study to specifically investigate whether the hypothalamus was
involved[ 6]. Two of the patients bad primary progressive (PP) MS and the remainder
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were in the secondary progressive phase, prior to autopsy. As is often the case in post-
mortem studies, the mean disease duration was long at 21 years (range 8 - 49 years) and
the majority of patients were chair- or bed-bound. Lesions were found in hypothalamic
grey matter in three patients. In four patients, axonal damage such as axonal swelling,
loss of axonal density and amyloid precursor protein deposition was evident in the
sections of hypothalamus. Overall 16 of the patient group had evidence of MS lesions in
the hypothalamus or within white matter structures, such as the anterior commissure,
internal capsule or optic system, adjacent to the hypothalamus. In addition, a high
proportion of these lesions were classified as active lesions.
Plaques have been previously reported in the hypothalamus ofMS patients
but none were identified on T2-weighted or PD imaging in our cohort of patients.
Certainly, considering the number of interconnections hypothalamic neurons have with
other structures, such as the thalamus, limbic system and brainstem nuclei, Wallerian
degeneration anterograde to a focal lesion could account for axonal loss. The patients in
this study do represent a proportion of the patients from the study in chapter 2. Therefore,
the widespread interconnections and a mechanism such as Wallerian degeneration could
potentially account for diffuse subtle pathological abnormalities affecting deep grey
matter structures. In this regard, T2 lesion volume did correlate significantly with Tt
relaxation times in our study and may support this mechanism. Similarly a significant
correlation was found between hypothalamic Tt relaxation time and disease duration.
This was something not demonstrated in the previous study of the thalamus and basal
ganglia but had been suggested by earlier studies ofTl relaxation times of the deep grey
matter in patients with early disease[14, 136].
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MRI based papers regarding involvement of the hypothalamus in MS have
predominantly involved case reports and therefore only conventional MRI techniques.
There have been a number of case reports involving patients with hypersomnolence
andlor temperature dysregulation typically with bilateral hypothalamic lesions[ II 0, Ill,
156, 157]. In addition, Ueno et at reported a patient with childhood MS who developed
right-sided hyperhidrosis with a contralateral hypothalamic plaque on MRI[I52].
A quantitative MRI based study has been undertaken in patients with a CIS
and at least two lesions on brain imaging, who are at high risk of developing MS[IS3]. In
this study, Henry et al investigated 41 CIS patients and 49 controls for whole grey matter
and focal grey matter atrophy. Although whole grey matter volumes were not different
between patients and controls, there was a significant difference in volume for a number
of grey matter areas when lesions were removed from the MRI analysis. These areas
include the thalamus, basal ganglia and left hypothalamus.
In MS patients, further studies have investigated the hypothalamus from
both an imaging and endocrine aspect. Kira et al assessed 27 MS patients and found that
one third had a mild-to-moderately elevated prolactin with further studies suggesting this
was due to hypothalamic dysfunction[155]. Overall the MS group had a significantly
higher prolactin than healthy controls. Four of the patients with an elevated prolactin
were found to have bilateral hypothalamic lesions on MRI compared to none of the
patients with normal prolactin.
Further, neuro-endocrine studies in MS patients have predominantly
concentrated on the HPA axis. These studies have typically been investigating the
hypothesis that neuro-endocrine dysfunction may play a role in the pathogenesis of MS,
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in particular the relationship between the HPA axis and immune system regulation. In the
animal model of MS, experimental allergic encephalomyelitis, it has been proposed that
susceptibility to developing the condition and disease activity may be related to an
inability of the HPA system to release sufficient corticosteroids to suppress the immune
system[ 158].
To this extent, Schumann and colleagues investigated 53 MS patients,
including 35 with RRMS, 13 SPMS and 5 PPMS, with the corticotrophin releasing
hormone (CRH) stimulation test[154]. In this test, IV CRH is administered followed by
serial measurements of cortisol and adrenocorticotropic hormone (ACTH) levels with
normally a rise of both. It is typically used to differentiate pituitary dependent Cushing's
syndrome (Cushing's disease), in which there would be an exaggerated rise in cortisol
and ACTH, from ectopic production (unaltered response). A subgroup of 45 patients also
underwent MRI imaging to look for GAD-enhancing lesions as a marker of disease
activity. The study found that patients with GAD-enhancing lesions had a significantly
lower cortisol response to CRH than patients without. In addition there was a significant
inverse correlation between the number of GAD-enhancing lesions and the cortisol
response to the CRH stimulation. It was felt that these results provided support for the
theory regarding the immuno-modulatory effect of the HPA axis in that high HPA
activity suppresses disease activity.
Wei and Lightman performed a number of neuro-endocrine investigations
as well as imaging in small groups of RRMS, SPMS and PPMS patients as well as
healthy controls[43]. On the CRH stimulation test there was a lower cortisol response in
SPMS patients as compared to controls. In addition, in patients with evidence of disease
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activity on MRI, the ACTH response to CRH was significantly higher and the cortisol
response to synthetic ACTH administration was significantly lower. Again therefore there
was some evidence of HPA axis dysfunction, namely central upregulation as well as
adrenal hyporesponsiveness, with some relation to markers of disease activity.
Fassbender at aI have reported a comparable study to Schumann's in
which they performed similar MRI and endocrine investigations on a group of 23 patients
with RRMS who were having an acute relapse[159]. Additional investigations included
serum and CSF markers of inflammation as well as a Questionnaire-based assessment of
depression and anxiety. They found that compared to healthy controls, MS patients had
overall a significantly higher response to CRH stimulation. There was a significant
correlation between depression and anxiety scores and the level of cortisol response to
CRR. In contrast to the aforementioned study, patients with GAD enhancing lesions had
a higher cortisol response to CRH. CSF white cell count, which could also be considered
a marker of CNS inflammation, was also found to correlate with a higher cortisol
response to CRH. These results suggested a role for dysfunction of the HPA axis in mood
disorders in MS. Similarly there was an apparent relationship between HPA dysfunction
and disease activity albeit the results are opposite to those of Schumann et al. The
investigators took the alternative position that the abnormal neuro-endocrine results are as
a consequence of immune activity.
Huitinga et al in a subsequent study to that described earlier, applied
further investigations to the same cohort of post-mortem MS patients[l60]. In this study,
the potential effect of inflammatory mediators produced in active lesions in or near the
hypothalamus on CRR and CRHNasopressin (VP) neurons was investigated. The
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number of active lesions was found to inversely correlate with the number of CRWVP
neurons suggesting that there is relative impairment of the CRH system in those patients
who have active lesions in and around the hypothalamus. It is of note that patients with a
higher degree of immunologically active MS also had a shorter disease duration
suggesting a worse disease course. This would appear to support the hypothesis that
dysfunction of the HPA axis is related to disease activity, possibly due to impaired
cortisol secretion leading to a lower ability to suppress immune responses.
3.4.2 MS-related fatigue - MRI correlations
Our study found no difference between TI value of the hypothalamus in RRMS patients
with and without fatigue and no correlation with fatigue severity. Therefore there was no
evidence to support a role for the hypothalamus in MS-related fatigue. However, the
potential for the hypothalamus to contribute to fatigue, especially in individual patients,
cannot be fully discounted, particularly considering the likely multi-factorial
pathophysiology offatigue in MS and also the small numbers in this study.
To summarise, we have demonstrated abnormal TI relaxation times in the
hypothalamus of a cohort ofRRMS patients. This confirms previous post-mortem studies
of involvement of the hypothalamus in MS and demonstrates that this quantitative MRI
technique may well provide a more comprehensive evaluation of the involvement of MS
than can be demonstrated by conventional MRI techniques. We have also found no
association between TI values, and the subtle pathological abnormalities this represents,
and MS-fatigue.
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CHAPTER4
Chapter 4. CSF HYPOCRETIN-l LEVELS, FATIGUE AND
HYPERSOMNOLENCE IN MS
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4.1 Introduction
In chapter 3, we have demonstrated a significantly prolonged TI relaxation time in the
hypothalamus in MS patients. As discussed previously, the hypothalamus may be
implicated in MS-related fatigue through a number of potential mechanisms, although
notably we found no association between fatigue severity and Tl values of the
hypothalamus in a small cohort ofRRMS patients.
One potential mechanism for MS-fatigue, and detailed in chapter 1, is
dysfunction of the hypocretin pathway. Hypocretin-containing neurons are located in the
hypothalamus and project widely to receptors within the cerebral cortex, limbic system,
brain stem and other deep grey matter structures such as the thalamus. Hypocretin-
containing neurons are present in a significantly reduced number in narcoleptic
patients[92]. Similarly, CSF hypocretin-l levels have been found to be frequently low or
absent in the CSF of patients with narcolepsy with cataplexy[96]. Narcolepsy is
characterized by excessive daytime sleepiness but narcoleptics also report fatigue[81]. In
MS, lesions within the hypothalamus have been shown. in case reports, to be associated
with hypersomnia and low CSF hypocretin-l levels[llO, 111]. There is the potential for
hypersomnia and fatigue to co-exist in MS patients and EDS may contribute to the
patient's perception offatigue[114].
4.1.1 ~s
To investigate this potential pathophysiological mechanism, we measured CSF
hypocretin-I levels in a cohort of patients with MS as well as other inflammatory and
non-inflammatory neurological conditions. Specific aims were: (i) to assess any
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relationship between hypocretin-l levels and fatigue severity, (ii) to evaluate any
relationship between hypocretin-l levels and hypersomnolence, (iii) to compare
hypocretin-l levels in MS patients to patients with other neurological conditions.
4.2 Materialsand methods
4.2.1 Subjedl
One hundred patients who were undergoing CSF examination at a tertiary neurology
centre were recruited. The group consisted of 58 females and 42 males with a median age
of 42.5 years (IQR, 35 - 51). The patients were separated into three cohorts. The first
group consisted of34 MS patients, as defined by McDonald's criteria[I43]. It comprised
22 females and 12 males. Twenty-six patients had RRMS, two had SPMS and six had
PPMS[142].
The second group was composed of 24 patients with other inflammatory
diseases. These included patients with neurosarcoidosis (n = 3), CIS (n = 8),
infective/inflammatory encephalitis or meningitis (n = 3), inflammatory demyelinating
polyradiculopathies or its variants (n = 10). The group comprised 7 females and 17 males.
The non-inflammatory diseases group comprised the remaining 42 patients
made up of 29 females and 13 males. This group included patients with benign
intracranial hypertension (n = 12), cerebrovascular disease (n = 6), primary headache
syndromes (n = 4), axonal peripheral neuropathies (n = 3) as well as a wide variety of
other conditions.
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4.2.2 CSF cOllectioD aDd hypocretiD measuremeDt
CSF was obtained by lumbar puncture in all patients between 9am and 5pm. It was frozen
immediately and stored at -80°C. The CSF hypocretin-l levels were measured in crude,
unextracted CSF using a custom-designed radioimmunoassay kit. Briefly, the hypocretin-
1 antiserum was raised in a rabbit immunised with hypocretin-I conjugated to bovine
serum albumin by carbodiimide. The 125-I-Iabelled synthetic hypocretin-l was prepared
by the direct iodogen method and purified by reverse-phase high performance liquid
chromatography. The antiserum did not cross react with any other hypothalamic peptides
including hypocretin-2. The assay had a sensitivity of 0.2 fmolltube with a 95%
confidence interval. Intra- and interassay variation was less than 10010.CSF was also
assessed for the presence of oligoclonal bands in 92 patients and the IgO index level in 90
patients in the hospital laboratory.
Approval was obtained from the Nottingham Research Ethics Committee.
All subjects gave informed consent.
4.2.3 Fatigue and hypenomDolence assessment
Fatigue was quantified using the FSS and excessive daytime sleepiness by the ESS in 78
of the patients[23, 60]. The questionnaires were ascertained on the day of the lumbar
puncture. The 78 patients consisted of 44 females and 34 males.
The MS group consisted of 14 females and 10 males, whilst the
inflammatory group consisted of 4 females and 13 males and the non-inflammatory group
consisted of 26 females and 11 males.
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Upon evaluating the FSS scores, two groups of patients were identified
within each cohort: fatigued patients (F) (FSS score ~ 5.0) and non-fatigued patients (NF)
(FSS score ~ 4.0). The outstanding patients, with a FSS score of between 4.1 and 4.9,
were not included in the F and NF group comparisons but their data was used in
correlation analyses.
Similarly, applying the ESS led to two further groups of patients being
identified within each cohort: patients with hypersomnolence (S) (ESS score > 10) and
those without (NS) (ESS score < 8). Again outstanding patients with an ESS score of
between 8 and 10, were not included in the S and NS group comparisons but were used in
correlation testing.
4.2.4 Statistiealaualysis
The Kruskal-Wallis H-test and Mann-Whitney U-test were applied to compare the
hypocretin-l levels of the MS, I and NI patient groups. The Mann-Whitney U-test was
also employed in comparisons between FINF and SINS cohorts. Spearman's rank
correlation coefficient (rho) was determined to assess correlations between the
hypocretin-l levels as well as clinical and questionnaire-derived parameters. A p value of
less than 0.05 was considered to be significant.
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4.3 Results
4.3.1 Baselinecharacteristics
Characteristics including age, FSS and ESS scores are summarized in Tables 4.1 and 4.2
as well as disease duration and number of relapses in the preceding 2 years for the MS
cohort. The median age of the patients with inflammatory diseases was significantly
higher than both patients with MS and non-inflammatory diseases (p = 0.024 and p =
0.041 respectively). In addition there were a significantly higher proportion of male
patients in the inflammatory cohort as compared to both the MS and non-inflammatory
groups.
There was a significantly higher FSS score in MS patients as compared to
those with non-inflammatory diseases (p = 0.002). In addition there were significantly
higher FSS and ESS scores in patients with inflammatory diseases as compared to those
with non-inflammatory disease (p = 0.044 and p = 0.028 respectively).
4.3.2 Hypoeretin-l levelsaDdintergroup analysis
MS. inflammatol)' and non-inflammatmy patients
The CSF hypocretin-l levels for the MS, inflammatory and non-inflammatory groups are
also reported in Tables 4.1, 4.2 and Fig 4.1, 4.2. There was a significantly lower
hypocretin-l level in the cohort of patients with inflammatory disease as compared to
non-inflammatory diseases, (p = 0.036). This result was reproduced by assessment of the
sub-group of 78 patients with fatigue and sleepiness data. Hypocretin-l levels were also
lower in patients with MS as compared to non-inflammatory disease however this only
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approached significance when assessing the subgroup of patients with questionnaire data
(p = 0.045). There was no significant difference in hypocretin-l levels between the MS
and other inflammatory disease cohorts.
Fatigued versus non-fatigued patients
Hypocretin-l results for patients with and without fatigue are reported inTable 4.3. There
were no significant differences in hypocretin-l levels between F and NF groups.
Hmersomnolent versus non-bypersomnolent patients
Hypocretin-l results are reported in Table 4.4. There were no significant differences in
levels between S and NS groups.
4.3.3 Correlation analysis
Fatigue correlation and bypocretin-l
There was no significant correlation between CSF hypocretin-l levels and fatigue
severity as assessed by the FSS in patients with MS, inflammatory or non-inflammatory
neurological diseases.
fbpersomnolence correlations and hypocretin-l
Similarly there was no significant correlation between tendency for excessive daytime
sleepiness as assessed by the ESS and CSF hypocretin-l levels in any of the disease
cohorts.
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Table 4.1 Characteristics of cohort of 100 patients
MS Inflammatory Non-inflammatory p Value
n=34 n=24 n=42
Age (years) 41.5 48.5 41.5 0.024*
(35 -49.5) (38 -63) (33 - 50) 0.041±
Disease-duration 3.5
(years) (2-7)
Relapse rate 2
(1-2)
Hypocretin-I 68.3 67.9 82.2 0.036±
(pmoVml) (56.4 - 91.4) (60.5 - 80.1) (68.3 -102.2)
Data are expressed as median (interquartile range)
Relapse rate is the number of relapses in the preceding 2 years
* Patients with inflammatory diseases compared toMS patients
± Patients with inflammatory diseases compared to those with non-inflammatory diseases
113
160.0
•
•
120.0 •
s: * •
~ • • I
Co • • I
.-fi' •G.I
•> •
~ I I~ 80.0 II I! I Ie I •Col ICl~= • •• I•
40.0 • •
•
•
.0
MS Inflammatory Non-inflammatory
Subjects
Fig 4.1 Scatterplot of hypocretin-I levels in cohort of 100 patients
* Patients with inflammatory diseases compared to those with non-inflammatory diseases
(p = 0.036)
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Table 4.2 Characteristics of subgroup of 78 patients with questionnaire data
MS Inflammatory Non-inflammatory p Value
n=24 n= 17 n=37
Age(years) 41.5 50 39 0.005*
(36-49) (41 - 69) (30 -50) 0.OO3±
FSS 5.4 5.8 3.7 0.00200
(4.4 -6.1) (3.5 -6.3) (2.6 - 5.1) 0.044±
ESS 10 10 6 0.028±
(5.3 -14.5) (7.3 -16.5) (4 - 10.8)
Disease-duration 3
(years) (2 - 17)
Relapse rate 2
(1-2)
Hypocretin-I 60.7 63.6 81.3 0.018±
(pmoVm1) (54.3 - 80.7) (52.3 -75.9) (67.2 - 98.1) 0.04500
Data are expressed as median (interquartile range)
Relapse rate is the number of relapses in the preceding 2 years
FSS = Fatigue Severity Scale; ESS = Epworth Sleepiness Scale
• Patientswith inflammatory diseases compared to MS patients
±Patients with intlammatory diseases compared to those with non-inflammatory diseases
00 MS patients compared to those with non-inflammatory diseases
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Fig 4.2 Scatterplot of hypocretin-I levels in cohort of 78 patients with
questionnaire data
* Patients with inflammatory diseases compared to those with non-inflammatory diseases
(p = 0.018)
± MS patients compared to those with non-inflammatory diseases (p = 0.045)
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Table 4.3 Hypocretin-I levels (pmoVml) in patients with and without fatigue
F NF P Value
MS 60.6 (54 - 80) 68.3 (56 - 81.3) 0.65
n= 17 n=4
Inflammatory 63.6 (49.9 -76.6) 64.3 (57.9 - 91.6) 0.57
n= 11 n=5
Non-inflammatory 94.3 (49.5 - 102.3) 73.2 (65.2 - 87.1) 0.22
n= 10 n=21
Data are expressed as median (interquartile range)
F = patients with fatigue; NF = patients without fatigue
117
Table 4.4 Hypocretin-l levels (prnoVml) ID patients with and without
hypersornnolence
S NS P Value
MS 60.6 (53.8 - 100.7) 69.7 (58.5 - 83.3) 0.38
n= II n=9
Inflammatory 70.1 (61.9 -77.7) 61 (52.9 - 83) 0.43
n=7 n=6
Non-inflammatory 91.3 (57.9 - 112.3) 80 (62.5 - 99.4) 0.43
n=9 n=22
Data are expressed as median (interquartile range)
S = patients with hypersornnolence; NS = patients without hypersomnolence
1I8
Clinical correlations and hypocretin-l
There was no significant correlation between hypocretin-l levels and age, disease
duration or relapse rate within any of the patient groups. These findings were reproduced
with analysis of the subgroup of 78 patients with questionnaire data.
Fatigue and hypersomnolence correlations
There were no significant correlations between FSS or ESS scores and clinical
parameters recorded in the patient cohorts. There were, however, significant correlations
between fatigue severity and daytime sleepiness in each of the patient cohorts; MS (rho =
O.473;p = 0.019), inflammatory (rho = 0.787;p < 0.0001) and non-inflammatory (rho =
O.377;p = 0.023).
4.3.4 Bypocretin-l and CSF constituents
CSF was positive for oligoclonal bands in 34 patients and negative in 58 patients. There
was no significant difference in hypocretin-l levels between patients who were positive
and those who were negative. Median IgO index was 0.55 (IQR, 0.47 - 0.83). There was
no significant correlation between IgO index and hypocretin-l levels.
4.4 Discussion
This study reports the CSF hypocretin-l levels in a group of patients with a variety of
neurological diseases under investigation at a tertiary neurology centre. The primary aim
of this study was to prospectively investigate for an association between hypocretin-l
levels and fatigue severity, assessed by the FSS, and hypersomnolence, assessed by the
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ESS, in a cohort of MS patients. It is, to the best of our knowledge, the first study to
prospectively evaluate and report on this potential relationship in MS.
4.4.1 CSF hypocretin-l, fatigue and hypenomnolence
We found no association between FSS or ESS scores and hypocretin-l levels in the MS,
inflammatory or non-inflammatory cohorts. Inaddition there was no difference in median
hypocretin-l levels between patients with and without fatigue or hypersomnolence. This
study, therefore, provides no support for the hypothesis that a potential
pathophysiological factor in MS-related fatigue is hypocretin dysfunction or deficiency
secondary to grey matter involvement in MS. This is despite finding supportive evidence
for an association between self-reported perception of the severity of fatigue and EDS in
all our patient cohorts.
There are a number of potential factors as to why no association was found
in our study should such a relationship exist. Firstly, it is quite likely that within a
population of MS patients, different pathophysiological mechanisms of fatigue exist
between individuals. In addition, as discussed within the introduction, it is also quite
likely that in a proportion of patients multifactorial mechanisms apply for generating
fatigue. These would include the variety of primary fatigue mechanisms discussed such
as immune-related, the neuroendocrine axis and autonomic nervous system dysfunction
as well as the factors implicated in secondary fatigue such as pain or deconditioning.
Within our study, potential confounding factors which may lead to secondary MS-related
fatigue were not addressed prior to CSF examination. These include, for example, a sleep
diary or withdrawal of potential medication which could lead to fatigue or
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hypersomnolence. This study was performed on patients who were admitted for lumbar
puncture as part of the management of their neurological symptoms or disease and as
such these, potentially relevant, factors were unable to be addressed prior to the
enrolment of subjects.
Further consideration must also be given to the patients who were enrolled.
In addition to the fact that the cohorts of patients were neither age- nor sex-matched,
there was a degree of selection bias in light of the fact that the patients were already being
admitted for lumbar puncture. This would suggest that, for example, the MS patients may
have active or early disease. Lumbar punctures are performed in patients to support a
diagnosis of MS and therefore most often performed in patients with a short disease
duration. In addition, the natural history of MS is that of a higher relapse rate initially
with a gradual reduction in frequency with disease progression. MS relapses may be
associated with destruction or dysfunction of the blood-brain barrier. Loss of integrity of
this barrier has been shown to determine CSF protein levels and could potentially lead to
alteration of levels of hypocretin-l[161]. It is of note, that our study revealed no
association between hypocretin-l levels and either disease duration or relapse rate within
the preceding 2 years.
The techniques applied to assess fatigue and hypersomnolence also need to
be considered as a potential confounding factor. Both the FSS and ESS, as discussed
within the introduction, are employed frequently in studies and have a number of benefits
including validity and reliability. Drawbacks however are rater bias as well as the
potential ceiling effect of the FSS. This could lead to a lack of differentiation between
degrees of fatigue severity within the cohort.
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Regarding the laboratory techniques employed, during the collection of
CSF, polystyrene containers were utilized. It has been recommended that, as a standard
for studies of CSF biomarkers, polypropylene tubes are used as they have a low protein-
binding potential[162]. It is therefore possible that the polystyrene tubes used during
collection may have altered the levels ofCSF hypocretin-l in our study. However, whilst
this effect has been demonstrated with other CSF biomarkers, there has been no such
study performed to determine the effect on hypocretin-I[163]. In addition, this potential
effect would be a constant within the study and should not have altered the inter-group
analysis or comparisons to clinical deficits.
A further confounding factor is the fact that the HLA status was not
assessed in the population of patients we studied. Both MS and narcolepsy are associated
with HLA sub-types and furthermore there is evidence that hypocretin-l deficiency in
narcolepsy may also be associated with HLA subtype[96]. It is therefore possible that
differentiating patients, within a study such as this, by lILA subtype would offer a clearer
picture regarding any potential association.
Two previous studies have investigated patients with other neurological
disorders and a potential association between EDS and hypocretin-l levels. Martinez-
Rodriguez et aI reported a cohort of six patients with myotonic dystrophy type 1 who
complained of hypersomnolence and evaluated them with the ESS and the MSLT[l06].
There was no correlation between either tool and hypocretin-l levels. A further study,
evaluated the hypocretin-I levels in ventricular CSF in 19 patients with advanced
Parkinson's disease. The investigators employed the ESS but again no correlation was
found( 107].
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Three studies have looked at hypocretin-I levels in relation to measures of
EDS in narcolepsy and other hypersomnias. One study evaluated 18 patients with
narcolepsy plus cataplexy and found no difference in ESS scores between those with
undetectable and detectable hypocretin-I levels[97]. They did however find significantly
shorter mean sleep latencies on MSLT in the cohort of patients with undetectable
hypocretin-I. This supported an earlier study of 106 narcoleptic patients that reported
more abnormal MSLTs in patients with low hypocretin-l levels[96]. A further study of
24 patients with narcolepsy with or without cataplexy and primary hypersomnia found no
correlation between hypocretin-Ilevels and ESS score or sleep latency[I64]' Considering
these studies, it is possible that objective measures of alertness or EDS may be a more
appropriate tool to investigate for any role of the hypocretin system in MS. We will apply
objective measures in the study reported in the following chapter
4.4.2 CSF bypocretin-llevels inMS
As discussed in the introduction, in addition to individual case reports of hypersomnia in
MS patients with hypothalamic lesions, there have been four previous studies assessing
groups of MS patients in terms of their hypocretin-I levels. Kanbayashi et at reported
eight MS patients whose CSF hypocretin-I levels were not significantly different from
patients without neuroimmunological disease[102]. Ripley et at studied 10 MS patients
amongst a cohort of patients with a wide variety of neurological disorders and found
levels within control range[165]. A study by Ebrahim et al found that low hypocretin-l
levels are present in some patients within a number of groups of neurological conditions,
including a cohort of 44 MS patients, however, the mean hypocretin-l level was within
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normal range[I05]. A study by Knudsen et al involved 23 RRMS patients and 25 patients
with optic neuritis[l13]. All but one patient had CSF hypocretin-l levels measured and
all were felt to be within normal range. In addition there was no difference in hypocretin
levels between those undergoing an acute attack and those who were stable. Our study, in
support of these previous reports, also found that although there is an apparent lower
level of hypocretin-l in patients with MS as compared to non-inflammatory conditions
this does not reach significance
4.4.3 CSF bypocretin-llevels in inflammatory disorden
Our study did find significantly lower hypocretin-l levels in patients with inflammatory
disorders, other than MS, as compared to non-inflammatory disorders. This again
supports earlier studies discussed in the opening chapter. A number of investigators have
reported significantly low levels in cohorts of patients with SLE, GBS and Miller-Fisher
syndrome[102-105]. In addition, narcolepsy is felt to have an autoimmune origin with its
HLA association and the recent report of a functional autoantibody[86]. The presence of
CSF oligoclonal bands andlor an elevated IgG index may be evidence for a CNS
immune-mediated disorder in individuals. Our study found no association between
hypocretin-l levels and either CSF marker.
One fmal point to note is our use of a custom-designed radioimmunoassay
kit rather than the commercially available radioimmunoassay employed in the majority of
referenced studies. We are confident that the measurements have internal consistency and
validity, as intra-lab variation has consistently been low. As an analogy, the intra-lab
coefficient of variation for CSF tau measurement is very low, whilst the inter-lab
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variation can be greater than 500/c,[166].In addition, inter-lab variation has been revealed
in studies which have use the same commercially-available radioimmunoassay for
hypocretin-l. For example, in one study comparatively very low levels were found in all
patients with narcolepsy without cataplexy and also those with primary hypersomnia
contrasting significantly with results from similar cohorts of patients in a study by
different investigators[96, 164].
To conclude, our study found no association between CSF hypocretin-I
levels and fatigue severity as assessed by the FSS or propensity to excessive daytime
sleepiness as determined by the ESS. We do report a significantly lower hypocretin-l
level in patients with inflammatory disorders as compared to non-inflammatory
conditions.
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CHAPTERS
Chapter S. MODAFINIL FOR MS-FATIGUE: A PUPILLOGRAPIDC STUDY
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5.1 Introduction
In chapter 1, a number of potential pharmacological and non-pharmacological treatments
for MS fatigue were discussed. The drug that has most recently been evaluated is the
wakefulness-promoting drug, modafinil. This drug has been shown to be effective in the
treatment of hypersomnia, in particular in narcolepsy. It has been shown to activate
neurons within deep grey matter structures such as the hypothalamus as well as the
brainstem[1l8]. The results of studies evaluating the effect of modafmil on MS-fatigue,
using questionnaire-based measures, are to-date mixed.
There are a number of physiological and laboratory techniques applied in
studies, such as the Pupillographic Sleepiness Test (PST), which provide objective and
reproducible measures of alertness and CNS vigilance. The PST has been shown to be an
effective measure of alertness in a number of, predominantly hypersomnolent, conditions
and can detect a treatment effect. However, it has been employed in only a limited
number ofMS studies.
5.1.1 ~s
Therefore to further explore the potential benefit of modafinil in MS-related fatigue, we
applied a number of objective, as well as subjective, tools to a cohort ofMS patients with
and without fatigue and healthy controls. The specific aims of this study were: (i) to
assess any effect of modafinil in participants as compared to placebo on measures of
alertness in particular pupillography, (ii) to evaluate for any difference in baseline
measures of alertness and vigilance in patients with and without fatigue, (iii) to compare
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baseline measures of autonomic function in participants and any effect of modafinil on
these measures.
5.2 Materials and methods
5.2.1 Subjects
Twenty-six patients with MS as defined by the McDonald's criteria were recruited[143].
The group consisted of 21 patients with RRMS, 3 with SPMS and 2 with PPMS[142].
There were 9 males and 17 females. All subjects were relapse and corticosteroid-free for
at least one month prior to commencement of the study as well as for the duration of the
study. No patients suffered from significant medical or psychiatric conditions that could
confound the study. Prior ocular manifestations of MS or impaired visual function, as
assessed by the Visual Function Questionnaire VFQ25, were exclusion criteria.
Subsequent to quantification of fatigue using the FSS, two groups of MS
patients were identified: fatigued patients (F) (FSS score ~ 5.0 [n = 16]) and non-fatigued
patients (NF) (FSS score $ 4.0 [n = 9])[23]. The single remaining patient, with an FSS
score of between 4.1 and 4.9, was not included in the F and NF group comparisons but
their data was used in correlation analyses. No patients with fatigue were receiving
medication that could potentially affect their fatigue. Three patients in each group were
receiving glatiramer acetate treatment and one patient in the NF group was receiving
intramuscular beta-interferon. One patient with SPMS was in the NF group whilst three
patients in the F cohort had chronic progressive disease.
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The normal control cohort consisted of 9 subjects matched in terms of
gender and age. The controls had no history of neurological disease or other significant
medical condition.
All participants completed the Beck Depression Inventory (BDI) upon
recruitment to evaluate for any clinically significant depression (a cut-off of <19 was
applied to indicate no or mild depression).
Approval was obtained from the Nottingham Research Ethics Committee.
All subjects gave informed consent.
5.2.2 Pupillograpbic measures of alertness
5.2.2.1 Pupillographic sleepiness test
A monocular, infrared television pupillometer (pST setup version 1.20: AMTech,
Weinheim, Germany) was used to measure pupil diameter in darkness. During each
recording session subjects wore goggles with infrared filters to ensure no visible light,
other than the pupillographic light source, entered the eye. The subject sat in a
comfortable chair with their head positioned on a chin rest 70em from the infrared
camera. White-noise [60 dB(A)] was supplied via headphones to mask external noises.
The subjects were instructed to fixate on the pupillographic light source, a red-light-
emitting-diode positioned at the level of the camera. The pupil diameter was measured
continuously for an 11 minute recording period at a frequency of 25Hz and provided the
mean pupil diameter. Software driven artifact rejection was applied to the raw data to
remove blinks and high-frequency noise. Oscillations of pupil diameter at frequencies of
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g).8Hz were captured and subject to Fast Fourier Transform. This provided the total
power of fluctuations. Absolute changes in pupil diameter were also recorded and
subjected to low pass filtering. These were obtained as the cumulative differences
between successive 0.64 seconds (16 data points at 25Hz) samples over 1 minute to yield
the pupillary unrest index (PUI). Data were captured by dedicated software (AMTech,
Weinheim, Germany) and stored for offline analysis.
5.2.3 NOD-pupillarymeasures of alertness
5.1.3.1 Critical Ricker fusioDfrequency
Critical Flicker Fusion Frequency (CFFF) is defined as the frequency at which a
flickering light gives rise to the subjective sensation of a steady light. Subjects sat
opposite a Flicker Fusion Monitor (modelll99, System 696 Ltd, London, UK) with four
light emitting diodes arranged in a lcm square on a black background. The mean offour
measurements of the threshold at which the light changed from flickering to constant was
obtained, two with increasing (flicker-to-fusion) and two with decreasing (fusion-to-
flicker) frequencies. With increasing vigilance, a higher threshold is achieved.
5.2.3.2 Choice reaetion time
Choice Reaction Time (CRT) provides an assessment of attention to a stimulus. It is as an
indicator of psychomotor performance and has been shown to be sensitive to
psychoactive compounds. Subjects were required to extinguish one of six equidistant red
lights, illuminated at random, by pressing the associated response button as quickly as
130
possible. Two components were recorded; Recognition- (RRT) and Motor Reaction Time
(MRT), which together are the Total Reaction Time (TRT). RRT was the time it took for
the subject to notice the light, the measurement being the time between stimulus onset
and the subject lifting their finger from the start button. MRT indexed the majority of the
movement component of this task and was the time between the subject having lifted
their finger from the start button and touching the response button. The mean reaction
times of 50 trials were recorded.
5.2.3.3 Speecb time
We used an example of automatic speech with subjects counting, taking their own time,
from 1 to 10. Specific equipment, constructed within the department, was used to analyse
this. The equipment involved a voice-operated timer which would begin at the first and
end at the last phonation. Upon detecting phonation, the counts were directed to a
'phonation' timer and upon detecting silence the counts were directed to a 'pause' timer.
Two values were obtained; phonation time and pause time. The phonation time was the
summation of the ten individual digit phonation times whilst the pause time was the
summation of the nine inter-phonation pause times. Both times are stable within normal
individuals, however, a prolonged pause time has been shown to be an indicator of
psychomotor retardation[167]. In addition, a decreasing pause time has been shown to
indicate a response to treatment[168].
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5.1.3.4 Visual analogue stale
Subjects rated their subjective state of mood using a computerized version of a visual
analogue scale (VAS) developed by Norris[169]. There are 16 scales subdivided under
three headings; alertness (nine items), anxiety (two) and contentedness (five), with rating
of these groups based on a factor analysis carried out by Bond and Lader[ 170]. Higher
scores in the 3 groups indicate increased alertness, calmness and contentedness
respectively. We specifically analysed the alertness score in subjects.
5.1.3.5 Digit cancellation
In this investigation the digit 4 was randomly distributed in a matrix of 400 digits
occurring 20 times in the whole sample. The subject had the task of crossing out the 4s as
fast and accurately as they could. The time to complete the task was recorded. To
minimize practice effects, four versions of these tests were prepared, and the subjects
received the four versions in a quasi-random order. The test has been shown to be
sensitive to psycho trophic compounds.
5.1.3.6 HypenomBolenu questionnaires
Patients completed the two most widely used questionnaires to assess sleepiness; the ESS
and the SSS[60, 64]. Whilst the SSS routinely provides an indication of the immediate
level of alertness of the patient, the ESS, on the other hand, is typically used to evaluate
the subject's sleepiness over recent times. However, in this study as the ESS was
administered both pre-and post-treatment, patients were asked to imagine how they
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currently feel in terms of alertness in the context of the eight scenarios depicted in the
ESS to also provide an immediate value of alertness.
5.2.4 Autonomic measures
5.2.4.1 Static pupillometry
Resting pupil diameter was measured with a binocular, infrared video pupillometer
(Procyon Ltd, London, UK) under four luminance levels (darkness, 6, 91 and 360 cdm")
achieved with a calibrated internal light source within the pupillometer. The
measurements were performed in a darkened room to prevent interference from external
light sources. The pupil diameter was first recorded in darkness and then under each
increasing luminance levels for two seconds at 4Hz and stored to disk for offline analysis.
5.2.4.2 Dynamic pupillometry ,
Pupil diameter during light and darkness reflex responses was measured with an infrared
binocular television pupillometer (TVC 101SB, Applied Science Laboratories, Waltham,
MA, USA) in a dark room. The sampling rate of the pupillometer was 60Hz and the
detection accuracy better than O.OSmm.
The stimulus for the light reflex response were four light flashes (green,
S6Snm peak wavelength) of200 millisecond duration and of incremental luminance (5.2,
41, 320 and 2050 cdm-2) measured in the plane of the cornea. The light flashes were
delivered at 25-second intervals, via a light-emitting-diode positioned 1cm from the
subject's right eye and providing "full-face" light stimulation. Two parameters were
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measured, firstly the amplitude of light reflex response i.e. the difference between the
initial and minimal pupil diameters to a light flash, which is a measure of the
parasympathetic response. Secondly, the 75% recovery time (T3/4), that is the time taken
to obtain 75% recovery from the peak of the pupil constriction and is a measure of
sympathetic activity.
Darkness reflex responses were evoked by switching on an illuminated
screen positioned 1m in front of the subject's eyes after a period of dark adaptation. The
luminance of the screen was 1370 cdm-2 and was switched on for 10 seconds. This was
followed by 20 seconds of darkness, a sufficient length of time for the dilatatory response
to darkness to reach a plateau. The cycle was repeated with the mean of two parameters
of darkness responses, measured. The parameters, both measures of sympathetic activity,
were the initial velocity (the time to obtain 25% of maximum dilatation from the onset of
the response, T 1/4) and the amplitude (the difference between dark- and light-adapted
pupil diameters).
5.2....3 Non-pupillary autonolDic measures
Blood pressure (BP) response to sustained handgrip is a non-invasive measure of
autonomic function. BP was measured with the subject sat down using an electronic
sphygmomanometer. They were then asked to achieve their maximum voluntary
contraction (MVC) using a handgrip dynamometer. Whilst recording BP every minute,
the subjects maintained handgrip at 20 per cent ofMVC. This was maintained for as long
as possible or for a maximum of 11 minutes. BP was recorded just prior to the release of
handgrip. The measurement obtained was the difference between diastolic pressure just
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prior to release and before starting. A normal response is an elevation in diastolic of
~16mmHg with $IOmmHg considered abnormal (11 - 15mmHg is borderline). This
pressor response is considered a measure of sympathetic activity.
5.1.5 thnmgJ
Modafinil 200mg and placebo were prepared in identical capsules and administered
orally. Modafinil has previously been studied in doses up to 400mg daily. In our study the
dose of modafinil was selected on the basis of a beneficial response at this dose in a large
muhicentre study of patients with narcolepsy[117]. In previous studies of modafinil in
patients with MS, there is evidence that, in those who respond, the majority do not need
to go higher than 200mg daily[ 131]. In addition, one study revealed a benefit at a lower
dose of 200mg but not the higher dose of 400mg daily[ 132].
5.1.6 Design
All subjects attended an acclimatization session at least one week prior to the first of two
experimental sessions which were themselves separated by a two-week interval. Subjects
were allocated to treatment according to a double-blind, balanced, crossover design.
5.1.7 Procedure
At the acclimatization session, as well as an introduction to the investigations, patients
completed the fatigue and depression questionnaires and underwent a full neurological
examination by an experienced observer. In the experimental sessions, pre-treatment tests
comprised hypersomnolence questionnaires, digit cancellation, VAS, PST, darkness
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reflex responses, CFFF, CRT, speech analysis and finally sustained hand-grip. The
capsule was ingested immediately after completion of the pre-treatment tests. Post-
treatment tests were carried out after two hours. The time course of the session was based
on the pharmacokinetic profile of modafinil with tmax being approximately two hours
following oral administration[171]. Post-treatment tests, in addition to the pre-treatment
tests, included static pupillometry and light reflex responses.
5.2.8 Statisticalanalysis
The Kruskal-Wallis H-test and the Mann-Whitney U-test were applied to compare the
autonomic and alertness measures between the F, NF and control groups. The Wilcoxon
Signed Rank test was used to compare response to modafinil with response to placebo
within each individual group. The Chi-Squared test was employed to assess the frequency
of normal responses to the pressor test within each cohort. Spearman' s rank correlation
coefficient (rho) was determined to assess for any correlations between fatigue,
sleepiness and pupillography results with other clinical and laboratory measures. A p
value of less than 0.05 was considered to be significant.
5.3 Results
5.3.1 Bueline characteristics
Control and patient groups were matched in terms of gender and age (Table 5.1). There
was no significant difference in terms of level of disability or duration of MS in patients
with and without fatigue.
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Scores on the BDI were found to be significantly higher in patients with
fatigue than patients without fatigue and healthy controls. However, it was noted that
only 3 subjects, who were all MS patients with fatigue, scored greater than 18 and no
patients had severe depression.
5.3.2 Baselinealertness measures
We compared the pre-treatment results of the pupillographic and non-pupillary measures
of alertness from the first experimental session undertaken by the subjects (Table 5.2). No
significant difference was found in baseline PST results between the 3 cohorts of
subjects. MS patients as a whole however, had a significantly lower CFFF as compared to
heahhy controls (p = 0.017). Interestingly, in patients with fatigue there was only a trend
for a lower CFFF (p = 0.057) whilst it reached significance in patients without fatigue (p
=0.019).
On the CRT investigation, we found a significantly prolonged TRT in MS
patients with fatigue as compared to controls (p = 0.012) which was due to a significantly
prolonged MRT (p = 0.024). There was no difference in RRT and nor was there any
significant difference between MS patients without fatigue and controls.
VAS alertness scores were significantly higher in controls as compared to
MS-fatigue sufferers (p = 0.004). There was however no difference between those
patients with and without fatigue. There were no other significant differences on the
additional questionnaire based investigations although there was a trend for higher ESS
scores in patients with fatigue as compared to those without but this did not reach
significance (p =0.057).
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Table 5.1 Baseline characteristics
F, n = 16 NF, n=9 Controls, n = 9 P Value
Age (years) 40.5 (35 - 52) 43 (31-45) 36 (30.5 - 53)
Sex, MIF 6/10 3/6 3/6
EDSS 2.5 (2-4) 1.5 (1.5 - 2)
Dis-Dur (years) 5 (3 - 11.5) 8 (5 -12.5)
FSS 5.6 (5.2 - 5.8) 2.3 (1.9 - 3.1) <0.001
BDI 7 (3 -12) 1 (0 - 3) 1 (0.5 - 4.5) <0.001*
Data are expressed as median (interquartile range)
F = patients with fatigue; NF = patients without fatigue; EDSS = Expanded Disability
Status Scale; Dis-Dur = disease duration; FSS = Fatigue Severity Scale; BDI = Beck
Depression Inventory
• MS patients with fatigue compared to patients without fatigue and healthy controls
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Table S.l Baseline alertness measures
F, n = 16 NF, n=9 Controls, n = 9 P Value
PUI (mm min-I) 4.44 4.07 3.48
(3.26 - 5.79) (2.69 - 6.27) (2.88 - 4.75)
Power 813 892 652
(638 - 1333) (487 -1285) (571 -799)
Mean Pupil 7.22 7.56 7.30
Diameter (mm) (6.20 - 8.40) (5.46 - 8.00) (6.70 - 8.47)
CFFF(Hz) 29.4 29.8 32.5 0.019*
(27.6 - 31.8) (25.1 - 30.1) (30.1 - 33.3)
TRT(ms) 690 685 607 0.014±
(633 -795) (646-716) (577 - 651)
RRT(ms) 386 369 378
(366-423) (250-404) (313 -403)
MRT(ms) 295 305 246 O.032±
(268 - 329) (290- 329) (225 -298)
Digit 60 49 47
Cancellation (s) (44 - 65.5) (46 - 54) (40.5 - 58.5)
ESS 6 3 5
(5 - 11) (0.5-8) (2- 5.5)
SSS 2 I I
(1-3) (1-2) (1-1)
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VAS 38.8 50.9 61.0 0.004±
(29.8 - 53.7) (39.0 - 65.7) (51.6 - 67.4)
Speech (s) 7.24 7.21 7.03
(5.82 - 9.52) (5.63 - 7.83) (5.84 - 10.77)
Phonation (s) 3.55 3.44 3.51
(3.16 - 3.84) (3.05 -4.17) (3.37 - 3.73)
Pause (s) 3.75 3.26 3.71
(2.33 - 5.76) (2.35 -4.21) (2.55 - 6.63)
Data are expressed as median (interquartile range)
F = patients with fatigue; NF = patients without fatigue; PUI = Pupillary Unrest Index;
CFFF = Critical Flicker Fusion Frequency; TRT = Total Reaction Time; RRT =
Recognition Reaction Time; MRT = Motor Reaction Time; ESS = Epworth Sleepiness
Scale; SSS = Stanford Sleepiness Scale; VAS =Visual Analogue Scale
• MS patients without fatigue compared to healthy controls
:!:MS patients with fatigue compared to healthy controls
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Table 5.3 Baseline sympathetic autonomic measures
F, n = 16 NF, n=9 Controls, n = 9 pValue
Sustained band- II 19 16
grip (mmHg)§ (6-23) (11- 24) (5 - 27)
Normal 34.4 66.7 58.8 0.028*
response (%)cx>
Darkness reflex 0.85 0.77 0.72
T 1/4 (mm S-I) (0.73 - 0.92) (0.72 - 0.90) (0.63 - 1.02)
Darkness reflex 3.85 3.92 3.86
amplitude (mm) (3.50 - 4.31) (3.50 - 4.30) (3.48 - 4.03)
T3I4(S) 1.43 1.54 1.41
5.2 cdm-2 (1.00 - 2.72) (1.24 - 2.21) (0.96 - 1.91)
T3/4(S) 1.85 1.74 3.09 0.004±
41 cdm-2 (1.49 - 2.72) (LSI - 2.19) (2.42 - 3.63)
T3/4(S) 2.82 2.88 3.13
320 cdm? (1.77 - 4.11) (2.34 - 3.84) (2.56 - 3.24)
T3/4(S) 3.44 3.12 3.20
2050 cdm" (2.06 - 5.01) (2.29 - 3.50) (2.65 - 3.85)
Data are expressed as median (interquartile range)
F = patients with fatigue; NF = patients without fatigue; Normal response = percentage of
patients with a normal response on the sustained hand-grip test; T 1/4= time to obtain 25%
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of maximum dilatation from the onset of the response on darkness reflex testing; T3/4 =
time taken to obtain 75% recovery from the peak of the pupil constriction on light reflex
response
§ Measure of the difference between the diastolic BP immediately prior to the
commencement and release of sustained hand-grip
ex> Patients with a normal response to sustained hand grip
• MS patients with fatigue compared to those without fatigue
±MS patients without fatigue compared to healthy controls
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Figure 5.1 Light reflex response: baseline T3/4 response of patients with and without
fatigue and healthy controls, clustered in four incremental luminance units. T3/4 is the
time taken from peak of constriction to obtain 75% recovery. Columns represent median
and interquartile range. Bars are extreme values.
F = patients with fatigue; NF = patients without fatigue; C = healthy controls
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Figure 5.2 Light reflex response (parasympathetic measure): baseline amplitude of
response of patients with and without fatigue and healthy controls, clustered in four
incremental luminance units. Columns represent median and interquartile range. Bars are
extreme values.
F = patients with fatigue; NF = patients without fatigue; C = healthy controls
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Figure 5.3 Resting pupil diameter: baseline pupil diameter of patients with and
without fatigue and healthy controls during static pupillometry, clustered in four
incremental luminance units. Columns represent median and interquartile range. Bars are
extreme values.
F == patients with fatigue; NF =patients without fatigue; C = healthy controls
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5.3.3 Baseline autonomic measures
We compared the baseline pupillary and non-pupillary measures of autonomic function
between the three cohorts. For the static pupillometry and light reflex response
investigations, which were not performed pre-treatment, we used the placebo post-
treatment session data. For all other autonomic measures we used the pre-treatment
results from the first experimental session (Table 5.3 and Fig 5.1 - 5.3).
The T3/04 response during the light reflex at 41cdm -2 luminance was
significantly slower in MS patients as compared to controls (p = 0.01). This remained
significant when comparing non-fatigued patients to controls (p =0.004) (Fig 5.1). There
was a trend for a slower response in patients with fatigue as compared to controls (p =
0.064). As indicated on Figure 5.1 there was a single extreme outlier in the fatigue cohort
with a very quick response. On removal of this outlier, this trend converted to a
significantly slower response in the MS-fatigue sufferers as compared to healthy subjects
(p = 0.023). There were, however, no significant differences in light reflex T3/4response
at other luminance levels and nor were there any difference between patients with and
without fatigue.
When comparing the pre-investigation and pre-release difference in
diastolic BP during the sustained hand-grip investigation, we found no difference in the
value between patient cohorts and healthy controls. However, it was noted that there was
a significantly lower number of normal responses in patients with fatigue (34.4%) as
compared to patients without fatigue (66.70At)fp = 0.028]. In addition there was a trend
for a lower number of normal responses when comparing the MS-fatigue sufferers to
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healthy controls (58.8%) [p= 0.l0]. We found no significant differences in other baseline
autonomic investigations.
5.3.4 Fatigue correlatioD. in MS patients
We found a significant correlation between level of fatigue as measured by the FSS and
mood as measured by the BDI (rho = 0.556; P = 0.004). There was a trend for higher
levels of disability as measured by the EDSS to correlate with a higher level of fatigue
but this did not reach significance (rho = 0.363;p = 0.068).
We also found a significant correlation between fatigue severity measured
by the FSS and level of daytime sleepiness as measured by the ESS (rho = 0.407; P =
0.039) (Fig 5.4). There was also a significant inverse correlation between the measure of
alertness as assessed by the VAS and the FSS scores (rho = -0.419; P = 0.033). No other
objective or subjective measures of alertness correlated with level of fatigue.
We investigated for any association between the autonomic measures and
fatigue severity but no significant correlation was found.
5.3.5 HypenolDnolenee correlation. inMS patients
On assessing baseline level of sleepiness as measured by the ESS, we found a significant
inverse correlation with duration of MS symptoms (rho = -0.443, P = 0.023). On the
alertness investigations we found a significant correlation between ESS score and RRT
(rho = 0.482; P =0.013) (Fig 5.5). Not unexpectedly, there were also significant
correlations with the questionnaire based measures of alertness, the SSS (rho = 0.732;p <
0.(01) and VAS (rho = -O.639;p < 0.001). With regard to the autonomic measures we
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Figure 5.4 Scatterplot of fatigue severity and hypersomnolence scores on FSS and
ESS respectively
FSS = Fatigue Severity Scale; ESS = Epworth Sleepiness Scale
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Figure 5.5 Scatterplot of the ESS scores and times of the RRT component of the
Choice Reaction Time test
ESS = Epworth Sleepiness Scale; RRT = Response Reaction Time
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found significant correlations with the ESS and resting pupil diameter on static
pupillometry at all four luminance levels [(darkness; rho = O.SOO;p = 0.009) (6cdm-2; rho
=0.424;p = 0.009) (9lcdm-2; rho = 0.428;p = 0.029) (360cdn12; rho = 0.479;p =0.013)].
5.3.6 PUI eorrelations in MS patients
There were no significant correlations of the PUI with any baseline demographic,
autonomic or non-pupillographic alertness measures.
5.3.7 Response to modafinil and ptaeebowithin individual groups
Within each of the three cohorts, for both the alertness and autonomic investigations, we
compared the response to placebo to that of modafinil.
5.3.7.1 Fatigue group
We found a significant reduction in two pupillograpbic measures of alertness; PUI (p =
0.02) and power of fluctuations (p = 0.03) after modafinil as compared to placebo (Fig
5.6 and 5.7). Figure 5.8 illustrates the significant increase in the CFFF threshold after
modafinil (p = 0.006) as compared to placebo. The MRT of the CRT was also
significantly quicker after modafinil in comparison to placebo (p = 0.015) (Fig 5.9).
Finally in terms of alertness measures, there was a significant reduction in the pause time
but not the speech time in MS-fatigue sufferers after modafinil as compared to placebo (p
= 0.028) (Fig 5.10).
Within the fatigue cohort we found significant differences in the
sympathetic, darkness reflex response post-modafinil as compared to post-placebo. There
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was a larger change in the amplitude of the response (p =0.012) and a quicker initial
velocity, T1I4,(p = 0.006) post-placebo compared to post-modafinil (Fig 5.11 and 5.12).
Static pupillometry was performed only post-drug treatment but we found a significant
difference in terms of pupil size at 6 (p = 0.039) and 360 (p = 0.01) cdm-2 patients post-
modafinil as compared to post-placebo but not at other luminance levels.
5.3.7.2 Non-fatigue group
There was no significant change in both pupillographic and non-pupillary measures of
alertness after modafinil as compared to placebo in MS patients without fatigue. Similarly
we only found a significant change in a single measure of autonomic function; resting
pupil diameter at 91 cdm" (p = 0.038). There was evidence of a trend for a lower
frequency of normal responses. to sustained handgrip after modafinil (11.1%) compared
to placebo (50.0010)[p = 0.079] but other autonomic investigations showed no significant
change post-placebo as compared to post-modafinil.
5.3.7.3 Control group
Results were similar to those of the non-fatigue MS group. There were no significant
changes found on alertness investigations. We again found a significant change on resting
pupil diameter at 91 cdm-2 after modafinil as compared to placebo (p = 0.028) and also on
a single measure in the light reflex response; the T3/4 at the 41 cdm -2 luminance (p =
0.038).
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Figure 5.6 Scatterplot of change in PUI post-placebo and post-modafinil in the MS-
fatigue group (p = 0.02)
PUI == Pupillary Unrest Index
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Figure 5.7 Scatterplot of change in total power of fluctuations post-modaflnil and
post-placebo in the MS-fatigue group (p = 0.03)
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Figure 5.8 Scatterplot of change in CFFF threshold post-modafinil and post-placebo
in the MS-fatigue group (p = 0.006)
CFFF = Critical Flicker Fusion Frequency
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Figure 5.9 Scatterplot of change in the time of the MRT component of the Choice
Reaction Time test post-modafinil and post-placebo in the MS-fatigue cohort (p = 0.015)
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Figure 5.10 Scatterplot of change in pause time on speech analysis post-modafinil and
post-placebo in the MS-fatigue cohort (p == 0.028)
156
e
e
~
1.5
l!
Q
C.
til
e •..
'"~
= 1.0
~
-e
....
Q
.s
e
:=
c.
~
.5
•
.9 I
~
~ I= I
".= II;J Id
e .0 • I
t;
e
•...
.!.
til •
Q
~
-.5
placebo modafinil
MS-Fatigue Group
Figure 5.11 Scatterplot of the change in the amplitude of the darkness reflex response
post-modafinil and post-placebo (p = 0.012)
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Figure 5.12 Scatterplot of change in T1I4 of the darkness reflex response post-modafinil
and post-placebo (p = 0.006)
T If4 = time to obtain 25% of maximum dilatation from the onset of the response on
darkness reflex testing
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5.4 Discussion
5.4.1 Baselinealertness
We found evidence of a significantly lower CFFF in MS patients as compared to controls.
CFFF as a measure is most frequently used in psychopharmacology to investigate for the
potential effects of medication on CNS vigilancelactivation[119, 172].
It has also been studied as an objective tool to identify minor cognitive
difficulties in patients with hepatic dysfunction. Minimal hepatic encephalopathy (MBE)
is defined as, otherwise unexplained, cognitive abnormalities only detectable on
psychometric or neuropsychological testing i.e. without evidence of overt
encephalopathy. A study by Sharma et al of 156 patients with cirrhosis found a lower
CFFF in those with MHE as compared to those without[ 173].
CFFF has also been employed in studies involving patients with
hypersomnia. Saletu et aI found a significantly lower CFFF in 17 treatment-free
narcoleptics as compared to healthy controls[174]. Similarly, Schneider at al found
significantly lower CFFF in small groups of 10 patients with narcolepsy and untreated
OSAHS as compared to controls[175].
This investigative tool has been applied in MS studies but primarily to
evaluate visual function as opposed to vigilance. In a study of 122 MS patients, 48% had
an abnormally low CFFF threshold, as defined as greater than three standard deviations
from the mean CFFF ofa group of28 healthy individuals[176]. This included 41% ofa
subgroup of 27 MS patients who denied any history of visual involvement whilst 51% of
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patients with current or previous visual involvement had abnormal CFFF thresholds. In
addition the frequency of abnormal CFFF results increased with increasing disability.
The question from this study arises as to whether in the MS group,
especially those without a history of visual involvement, the abnormal CFFF was due to
subclinical optic neuropathy or impaired CNS vigilance.
In another study of 23 MS patients the mean CFFF threshold was
significantly lower than that of healthy controls with 39010felt to have an abnormally low
value[l77]. This however compared to 78% of the MS patients having abnormal visual
evoked potentials (VEPs). This may suggest that VEPs are more sensitive at detecting
optic nerve demyelination. Alternatively, the two investigations may measure either
different pathologies or evaluate different systems, such as visual and cognitive. It is of
note that in the same study, of seven patients with optic neuritis, five had abnormal CFFF
thresholds but two of these had normal VEPs which suggests that conversely VEPs are
not necessarily more sensitive at detecting demyelination.
In patients with definite MS, a study has shown a significant reduction in
CFFF threshold with increasing body temperature[178]. This was the opposite response
to that seen in healthy controls. Whilst, in view of this correlation with Uhthoff's
phenomenon, this study may support the CFFF as a tool for assessing optic nerve
dysfunction, vigilance and fatigue may also be exacerbated by heat in MS.
As mentioned in the introduction, aminopyridines are potassium channel
blockers that prolong the duration of the action potential and potentiate synaptic
transmission. They have been evaluated as a symptomatic treatment potentially effective
against intermittent conduction block. Ina placebo-controlled study involving 20 patients
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with temperature-sensitive MS, the effect of 4-Aminopyridine on 'visual function', which
comprised visual acuity and CFFF analysis, was evahiated] 179]. Although the CFFF
aspect was not reported separately for all patients, there was a significant improvement in
visual function with treatment. This could be explained by improvement in vision, as
there was also a significant decrease in PI 00 latency with treatment, but it is of note that
aminopyridines have provided a subjective benefit inMS-fatigue.
In our study, there was a significantly lower CFFF threshold in MS
patients as compared to controls. These results would support lower levels of vigilance
and attention in MS although the contribution of visual dysfunction cannot be completely
discounted. Indeed, patients with fatigue had a lower CFFF threshold than controls but
this did not reach significance. The potential impact of fatigue on CNS vigilance as
measured by the CFFF could be reassessed by a further study with a larger cohort of
patients.
Our study also found a significantly prolonged MRT in MS patients with
fatigue as compared to controls. There was no difference however between patients with
and without fatigue nor was there any difference between non-fatigued patients and
controls. The MRT is the time from the subject's finger being lifted off its original
position to when it reaches the button associated with the light that has come on. This
time, as its name suggests, is primarily a measure of motor speed rather than information
processing. It would be influenced by disability affecting the upper limb, for example
weakness or ataxia, as well as visual function. It is of note that the EDSS was not
significantly different between the MS groups however individual motor and cerebellar
Functional System scores, which may be more relevant, were not evaluated.
161
A number of studies by different groups have been undertaken to evaluate
choice reaction time in MS patients primarily to assess information processing speed. A
wide variety of methodologies and equipment have been used thus making comparisons
difficult. An example of one such study was that undertaken by Reicker at al which
employed simple, choice and semantic Reaction Time (RT) tests in a cohort of 60 MS
patients and 60 healthy individuals[180]. The simple RT test involved pressing the space
bar when the letter 'X' appeared on a screen. The choice RT test involved two different
stimuli (the words 'duck' and 'kite') with the subject having to press one of two buttons
depending on which word was presented. Finally, the semantic RT test required patients
to allocate a variety of different words presented individually into a number of different
categories represented by different buttons. Overall, MS patients had prolonged RTs
compared to controls with increased divergence ofRTs with increasing complexity of the
task. Whilst RTs were not separated into their cognitive and motor components and it was
felt that motor dysfunction could account for some of the difference between cohorts,
there was also evidence of cognitive dysfunction particularly by the increasing difference
in groups with complexity. This study supports the idea that CRT can be employed to
assess information processing in MS but again direct comparison between our study and
previous studies remains difficult.
5.4.2 BaseliDe autoDomic
Autonomic dysfunction is common in MS with one study showing 90010of patients
complaining of at least one autonomic symptom with, as expected, the most common
symptoms relating to sphincter control[181]. Cardiovascular symptoms are less common,
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with between 24 - 54% complaining of orthostatic dizziness[181, 182]. Our study found
some evidence of cardiovascular autonomic dysfunction with an abnormally low number
of normal responses to sustained hand-grip in MS-fatigue patients. This supports a
number of previous studies which have also found some evidence of autonomic
dysfunction on cardiovascular reflex function tests. Typically tests include heart rate
response to deep breathing, valsalva and standing as well as BP response to standing and
isometric hand-grip.
Gunal et al reported that in a cohort of 22 RRMS patients, 10 patients
(45%) had at least one abnormal cardiovascular test compared to no abnormal tests in the
control group[181]. Three patients (14%) were classified as having autonomic
dysfunction on the basis of two or more abnormal tests. The most common abnormality
was found on heart rate response to breathing. Inthis study however, only a single patient
bad an abnormal response to sustained hand-grip. In a similar study, four MS patients
(25%) from a cohort of 16, had abnormal cardiovascular reflexes although only one
patient (6%) had autonomic dysfunction.
A further study utilizing the same cardiovascular investigations was
performed on 40 MS patients and found similar results with four patients (10010)classified
as having autonomic dysfunction[182]. The most frequently abnormal test in this study,
however, was isometric hand-grip with a normal response occurring in only half the
patients. This study also reported a correlation between the presence of autonomic
dysfunction and MRI lesions in the brainstem.
Sterman and colleagues employed a slightly different battery of
cardiovascular reflex tests, including heart rate and BP response to cold but not hand-
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grip, and detected autonomic dysfunction in 9 of22 patients (41%)[183]. Again the most
frequently abnormal test was that of heart rate response to deep breathing. In addition
they found a correlation with an increasing number of abnormal autonomic tests and
sphincter disturbance on the Kurtzke Functional Score.
A study performed by Pepin and colleagues assessed isometric hand-grip
in 104 MS patients[I84]. Eighteen patients (I?OAt)failed to achieve a normal response
compared to none of the normal controls (N = 25). In our study, we found a much higher
number of patients who failed to achieve a normal response compared to this earlier
study. There are a number of methodological differences between the studies. In our
study, the exercise was performed at 200Atas opposed to 30% of MVC. In addition, the
duration of the exercise was capped at 11 minutes if the subject had not fatigued prior to
that. In the Pepin study the mean time to fatigue was approximately four and a half
minutes. They also employed equipment that performed beat-by-beat BP monitoring
whilst we performed serial electronic measurements including one just prior to release.
If patients failed to reach fatigue by 11 minutes in view of the lower work
rate required, then this potentially could lead to false positive results, however, the
majority of MS patients reached fatigue prior to this cut-ofF. Similarly, the fact that the
controls more commonly achieved a nonnal response with the same protocol suggests
that the work rate was adequate to induce a pressor response. Both studies may be subject
to patients perceiving fatigue earlier and therefore shortening the duration of the test.
However, this argument is counterbalanced by results from the Pepin study which
identified a lower BP rise in MS patients, compared to controls, at all stages of the test
and not just at the fatigue point.
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This study found a significantly lower number of normal BP responses to
isometric hand-grip in patients with fatigue as compared to those without. This does raise
the possibility of autonomic dysfunction contributing to MS-fatigue. We do note that
there was little evidence of autonomic disturbance with pupillary autonomic testing, in
MS as compared to healthy controls, and no significant differences in these pupillary
measures between patients with and without fatigue. Two previous studies have
investigated the potential relationship between autonomic function and fatigue in MS and
have provided conflicting results.
Flachenecker et al investigated 60 MS patients and 30 controls with
cardiovascular reflex testing and fatigue questionnaires[ 48]. They found a significantly
lower heart rate response to standing in patients with fatigue as compared to those
without as well as healthy controls. Both the orthostatic heart rate response and the
isometric handgrip results correlated significantly with fatigue scores. It was felt that this
study provided evidence for a relationship between sympathetic dysfunction and fatigue.
In a study involving 84 MS patients, Merkelbach et al evaluated the results
of cardiovascular reflex tests and a number of questionnaire-based fatigue scores[46].
They found that 27% of patients had evidence of autonomic dysfunction, with the
isometric hand-grip test most frequently abnormal. Patients with SP- or PPMS were more
frequently affected than patients with RRMS. There were no significant correlations
between autonomic tests and any of three fatigue scores. Weak correlations were only
noted when patients were divided according to type of MS with different fatigue scores
correlating with different autonomic tests in SPMS. However, incongruent results were
also found including less impairment of orthostatic BP response in RRMS patients with
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fatigue. Overall it was felt from this study that the relationship between fatigue and
autonomic dysfunction appears weak.
The results of our study do add some support to the suggestion that
cardiovascular autonomic dysfunction may contribute to MS-fatigue. We do
acknowledge that our study involved a small number of patients compared to the two
reports described above and only a single cardiovascular reflex test as compared to a
number of other studies described earlier. The complaint of fatigue is likely to have a
multifactorial basis in a heterogenous population of MS sufferers and as such autonomic
dysfunction may well playa significant role in a number of individual patients although it
is difficult to conclude as to whether it is a frequent significant contributor to fatigue in
the MS population as a whole.
5.4.3 Fatigue and hypenomnolence correlations
We found no correlation between subjective measures of fatigue and sleepiness and our
primary objective measure of alertness, pupillography. We did find a significant
correlation between EDS severity as assessed by the ESS and the RRT component of the
CRT. As discussed earlier, various tools assessing CRTs have been employed in MS and
these have provided some evidence of dysfunction of information processing. We found
no significant baseline difference in RRT between patients with and without fatigue nor
any association between fatigue severity and RRT. Although our findings suggest that
patients with higher levels of EDS have slower information processing, it is important to
recognise that there still remains a motor component to the RRT score. The RRT
comprises a motor aspect with the patient having to lift their finger from a button as well
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as the cognitive aspect. Our study found no correlation between autonomic measures and
fatigue, sleepiness or pupillography.
5.4.4 Response to modaf'mil
In this study, to the best of our knowledge, we are the first to report the effect of
modafinil on MS-fatigue using objective measures of alertness and vigilance, as well as
the subjective questionnaire-based measures which are commonly used in such studies.
The main methodological flaw is the small number of subjects in each cohort however as
a pilot study it provides a basis for a further larger study to determine further the role of
modafmil. We have however demonstrated that in patients with fatigue there is a
response to modafinil in terms of pupillographic measures of alertness, CFFF threshold,
CRT measures and the pause time of automatic speech.
As discussed in chapter 1, only a small number of studies have previously
reported the use of the PST in MS patients. A number of methodological differences
apply between our investigation and previous studies. Firstly, in the study by Egg and
colleagues, a larger number of patients were recruited but the group was more
heterogenous with a significant number of patients with a single attack, undergoing an
acute relapse or on treatment with interferon-beta[78]. Only a single measure from the
PST investigation, the PUI, was determined. Ahhough the FSS was used, patients were
not separated into those with and without fatigue and simply correlation analysis was
performed. In addition, they were primarily utilizing pupillography as a measure of
autonomic imbalance rather than of alertness. Their study reported no significant
difference in terms of pm between patients and controls. The baseline results of our
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study support this finding. They did however find an unexpected, significant inverse
correlation between PUI and fatigue severity in the MS group. This would suggest a
rather contradictory, higher degree of fatigue according to the FSS was associated with a
bigher degree of alertness as determined by the lower PUI. Their conclusion was that
autonomic instability was not associated with MS fatigue severity.
A further report by the same group, also used a similar larger but more
heterogenous MS cohort[1l3]. Hypersomnolence was evaluated but not fatigue.
Medication that could potentially contribute to EDS were only excluded on the day of the
investigation. They found no difference in PUI between patients and controls and no
correlation between PUI and self-reported EDS. Again the baseline results of our study
support their findings.
Although there was no correlation between any PST measure and fatigue
or sleepiness severity, we have found a significant reduction in the PUI and the power of
fluctuations with modafinil, as compared to placebo, in patients with fatigue. This
indicates that patients with MS related fatigue show an increased alertness with
modafmil. This response was not seen within healthy subjects or MS patients without
fatigue.
Speech time, whilst infrequently employed as a tool in studies, has been
shown, predominantly in neuro-psychiatric disorders, to be a measure of psychomotor
retardation. This is to the best of our knowledge the first study to employ speech time
analysis in MS.
Hoffinan et al noted that 12 patients with a unipolar affective disorder had
a significantly prolonged pause time as compared to controls and this correlated with a
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clinically-evaluated scale of psychomotor retardation[167]. In a 1976 report, Szabadi et at
described four patients with moderate severity depression in whom they assessed
automatic speech[168]. Phonation time remained constant but was variable between
individuals. Pause time, however, significantly decreased with recovery from depression.
There was no change in pause time in four healthy subjects and therefore the
improvement could not be explained simply by practice effect.
A study involving 13 schizophrenic patients undergoing an acute
exacerbation detected a longer mean pause time in a rote- (automatic) speech task as
compared to controls[185]. They did however feel that tasks with higher cognitive and
linguistic demands (speech analysis of a description of a cartoon) would more readily
detect differences between controls and schizophrenic patients. However this, so-called,
free-speech task would not lend itself as well to repetitive assessment such as that
required for investigating a treatment effect and explains our use of automatic speech in
measuring a response to treatment in this study.
It is noted that BDI scores were higher in patients with fatigue than those
without or healthy controls. Therefore, it might be suggested that the response to
modaflnil in this cohort is due to the effect on psychomotor retardation which might
occur in patients with depression. There have been limited studies into the potential use
of modafinil either as primary or adjunctive treatment in depression and, to-date, the
evidence does not support the use of modafinil in the treatment of depression[186]. In
addition, although there was a significant difference in BDI scores between the cohorts,
neither the frequency nor severity of depression were great in the fatigue cohort.
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It was noted that there was a significant improvement with modafinil in the
MRT component of the CRT in patients with fatigue. There was no significant
improvement in patients without fatigue and healthy controls. Although the RRT was not
significantly different compared to placebo, it is possible that this result is also indicative
of an improvement in psychomotor function.
CFFF as a tool has been used in healthy controls to compare psychoactive
drugs and has been shown to have the potential to detect the effect of treatment. Hou et aI
demonstrated, with a reduction in CFFF threshold, the sedative effect of the anti-
histamine diphenhydramine, as compared to placebo, in a cohort of healthy subjects[172].
As discussed earlier, we found evidence of a significantly lower CFFF in
MS patients as compared to control and this supports the findings of a number of
previous trials employing CFFF in MS. The question is raised as to whether this provides
evidence, as suggested by previous studies, of visual impairment or whether it is
indicative of impaired vigilance. It is of note that we found that a significantly higher
CFFF threshold post-modafinil as compared to placebo in patients with fatigue. It is not
readily conceivable how modafinil might affect visual function. In addition we found no
significant difference in MS patients without fatigue and it would have been likely that if
the higher threshold was due to improved visual function, then this result would have
been reproduced in this cohort. We feel this finding supports the concept that CFFF is at
least in part a measure of vigilance. We found no significant difference in CFFF with
modafinil as compared to placebo in healthy individuals. This supports the previous
findings of two separate studies in which modafinil was shown to have no significant
effects on CFFF threshold in healthy subjects(119, 172].
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In terms of autonomic measures, we did find significant changes in the
darkness reflex responses in terms of the amplitude and the initial speed of response (both
indicative of altered sympathetic activity) with modafinil, as compared to placebo, in the
MS-fatigue group. There has previously been rather mixed results with modafinil in
regards to the darkness reflex in earlier studies involving healthy individuals. One study
showed no effect whilst an earlier study showed an increase in initial velocity with
modafinil but no change in amplitude[1l9, 172]. Although we only found limited
evidence of autonomic disturbance both at baseline and with treatment it is conceivable
that modafinil could affect autonomic measures. As discussed previously, modafinil has
been shown to activate a number of cell groups which are involved in an arousal
network[l18]. This network includes noradrenergic neurons which project from the Le to
the cerebral cortex as well as influencing other nuclei such as the TMN. The question,
however, of whether modafinil has a direct or indirect effect on sympathetic activity is as
yet unanswered.
Overall, our study provides evidence, with a number of objective
measures, of a benefit with modafinil in terms of alertness and vigilance in patients with
MS-fatigue. Again as discussed in the introduction, a number of studies have evaluated
the potential use of modatinil in MS-fatigue but with varied results. Notably, the two
earliest reported studies both had methodological flaws. The first by Zitko et al found a
significant improvement in both ESS and FSS after three months treatment however this
was an open-label, non-placebo-controUed study[131]. A study by Rammohan at al found
a similar improvement in ESS and FSS as well as the MFIS after two weeks treatment
with modafinil 200mg[132]. It is of note, however, that this was a single-blind study
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albeit with a crossover, placebo arm. The response did not persist with an increased dose
of modafinil 400mg possibly suggesting a placebo effect that waned with time. In
addition, ESS was not measured after placebo but rather post-modafinil scores were
compared to a baseline measurement.
Stankoff et al reported in 2005 a large double-blind, placebo-controlled
study in which they found no significant difference between treatments after five weeks
in either MFIS or ESS[133]. They did however comment on unpublished post-hoc
analysis which suggested a differential effect modafinil may have on the physical aspect
of the MFIS score in patients with, as compared to those without, excessive daytime
sleepiness as determined by the ESS.
We also note the lack of response to modafinil in the non-fatigued and
control cohorts on PST, CFFF and speech measures. This supports previous studies
which have shown a limited effect of modafinil on cognitive tests as well as fatigue and
sleepiness questionnaires in healthy subjects[187]. It is noted however that there are
mixed results on previous studies assessing the response of PST measures to modafinil in
healthy individuals. One study demonstrated no significant difference in PUI with
modafinil as compared to placebo although in a second study by the same group a
significant reduction in PUI was found( 119, 172]. Overall, however, we feel that this lack
of response in other cohorts, supports the concept, suggested by Stankoff et al in their
post-hoc analysis, that the response to modafinil is not based on a class effect but rather
there is a differential effect. In their study it was determined both by type ofMS and ESS
score or rather the presence of hypersomnolence, whilst in our study it was the presence
of fatigue.
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A question that arises from these results is to what these
neurophysiological and laboratory tools are specifically measuring and, although
objective, whether these provide any quantitative assessment of MS fatigue. MS fatigue
is almost certainly multifactorial within groups of patients and may even be so in
individual patients. It could be argued that questionnaire based assessment and detection
of MS-fatigue is a non-specific measure and does not distinguish between aetiology of
fatigue. In addition, rater bias and ceiling effects contribute to the problems of fatigue
questionnaires.
It is likely that in some MS patients with fatigue, that one or more of
alertness, sleepiness, CNS vigilance and psychomotor retardation are contributing to the
symptom of fatigue. For example, from previous studies it is evident that some MS
patients will perceive that a liability to drop off to sleep in the day is a component of
fatigue and vice versa[114]. Therefore, we feel it is likely that the finding of a benefit
with modafinil in measures of these symptoms is relevant to some patients and may
indicate a role for modafinil in some patients with MS-fatigue. Isolating those patients in
clinical practice, inwhom the benefit is most likely to occur, is the difficult factor.
To conclude, this study demonstrates the first objective, laboratory and
neurophysiological evidence of improvement in measures of alertness, vigilance and
psychomotor retardation with modafinil in patients with MS-fatigue. It supports a role for
modafinil in the treatment of MS-fatigue although further studies may be important to
identify if certain sub-groups of fatigue sufferers would respond best to treatment.
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CHAPTER6
Chapter 6. SUMMARY AND CONCLUSIONS
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6.1 Summary
This thesis began by presenting a brief general overview of MS. Although traditionally
considered a white matter CNS disease, the evidence of involvement of grey matter and
in particular deep grey matter structures in MS was described. Fatigue, a frequent and
major symptom in MS, was then discussed in detail. A number of potential mechanisms
have been proposed as to the pathophysiology of MS-fatigue and several of these
processes imply a key role for deep grey matter structures. Disruption of cortico-
subcortical circuits that involve cortical grey matter and the basal ganglia and thalamus
has been suggested by studies involving advanced imaging tecbniques[17, 58].
Autonomic dysfunction has been demonstrated, including with cardiovascular reflex
function tests, to be present in MS patients and may contribute to MS-fatigue[48]. This
suggests a role for the hypothalamus, from which descending autonomic neurons
originate. Neuroendocrine disturbance has also been suggested as contributing to MS-
fatigue. This further implicates the hypothalamus through its neuroendocrine function
with neurons projecting towards and stimulating secretion of hormones from the
pituitary.
The introduction also discussed a component of the arousal network, the
hypothalamic hypocretin-containing neurons. These have been demonstrated to be
reduced in number, potentially through an autoimmune mechanism, in narcolepsy[92].
Dysfunction or deficiency of the hypothalamic hypocretin pathway could also contribute
to MS-fatigue. Whether a disorder of a pathway which primarily leads to EDS may also
contribute to fatigue is somewhat contentious. It is, however, reasonable to consider that
impaired alertness in subjects may contribute to a sense of fatigue. There is evidence of
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an association between self-reported fatigue and hypersomnolence in a variety of
conditions including MS[ll4].
The work presented in this thesis explored the role of the deep-grey matter
in MS-fatigue. Conventional MRI techniques, whilst essential for the diagnosis of MS,
have been relatively less effective at providing a correlation with symptoms and
disability. In addition, conventional MRI is limited in its ability to demonstrate lesions
and abnormalities in the grey matter of MS patients. It was illustrated in the introductory
chapter the value of non-conventional MRI techniques, including quantitative MRI
modalities, both in terms of their closer association with clinical features and their
application to small structures.
In the first study we applied a quantitative MRI technique, Tl relaxation
time measurement, to three deep grey matter structures in a cohort of RRMS patients.
Using the FSS questionnaire, patients were evaluated in terms of their fatigue.
Significantly higher median Tl values were demonstrated in the thalamus and putamen,
as compared to healthy controls. This has not been demonstrated on previous Tl
relaxation time studies of RRMS patients. In addition, we found significantly higher
median Tl values of the thalamus in patients with fatigue as compared to those without.
A significant correlation between the T 1 value of the thalamus and fatigue severity was
also shown. The abnormal Tl values of these deep grey matter structures, although
indicative of subtle pathological abnormalities, and potentially a consequence of diseases
processes, such as Wallerian degeneration, were not associated with the most overt MRI
evidence of disease burden, the T2-lesion load. It was noted that T2 lesion volume, in
support of previous studies, was not associated with fatigue severity. This study
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supported the value of quantitative MRI techniques in providing a more comprehensive
picture of disease burden. In addition, it endorsed the assertion of previous studies that
non-conventional MRI modalities may provide a better correlation with symptomatology.
Similarly it provided supportive evidence for a role of the thalamus in MS-fatigue
possibly through disruption of cortieo-subcortical circuits.
The second study to be presented in this thesis expanded on this finding by
applying Tl mapping to another deep grey matter structure, the hypothalamus, in a cohort
ofRRMS. The hypothalamus, although involved in MS, has not been previously assessed
by quantitative MRI techniques. The same method of Tl relaxation time measurement
was applied whereby the largest volume of the structure was included whilst avoiding
contamination from neighbouring white matter or CSF. With this approach, the study
demonstrated a significantly higher Tl value in MS patients as compared to healthy
controls. This finding endorsed the conclusions derived from the first study and suggested
that a diffuse process may be affecting these interconnected deep grey matter structures.
To this extent, and in contrast to the first study, T2-1esion volume was associated with the
hypothalamic Tl value. Also in this study, and in light of the potential involvement of the
hypothalamus in a number of fatigue mechanisms, fatigue severity was measured in the
cohort. No significant association with FSS scores was shown.
Having provided evidence for the presence of subtle abnormalities within
the hypothalamus inMS, its potential relationship to fatigue was further explored in the
third and fourth studies presented in this thesis. In the third study, although we had
previously found no evidence of an association between an MRI-derived measure of the
hypothalamus and fatigue, we employed a laboratory technique to further assess the
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hypothalamus and more specifically the hypocretin pathway. As detailed in the
introduction, the measurement of CSF hypocretin-l levels has been clearly shown to
demonstrate involvement of the hypocretin system in conditions such as narcolepsy[96].
In addition, levels have been shown to be associated with the severity of
hypersomnolence[97]. Low CSF hypocretin-I levels have been demonstrated in a number
of other conditions including cases of secondary hypersomnia and inflammatory
disorders[llO, Ill].
In this third study, as well as CSF hypocretin-l levels, we prospectively
measured both fatigue severity and propensity to EDS with questionnaires in cohorts of
patients with MS, inflammatory and non ..inflammatory neurological disorders. Although
CSF hypocretin-l levels have been previously measured in cohorts of MS patients, its
potential relationship to clinical features has not been studied. The addition of a
measurement of hypersomnolence in this study was important to allow patients to be
differentiated according to EDS as well as fatigue although it was noted that FSS scores
correlated significantly with ESS scores in all cohorts. The study demonstrated
significantly lower CSF hypocretin-l levels in patients with inflammatory diseases other
than MS as compared to the non-inflammatory cohort. There was, however, no
significant difference between the MS group and the other patient cohorts. In addition, we
found no association between fatigue or EDS severity and hypocretin-l levels and no
difference in hypocretin-l levels between patients with and without fatigue or
hypersomnolence. This suggested that hypocretin dysfunction or deficiency secondary to
grey matter involvement in MS is not a significant or frequent factor role in MS-fatigue.
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A further potential hypothalamic role in MS-fatigue, that of autonomic
dysfunction, was addressed within an arm of the fourth and final study presented in this
thesis. Baseline investigations included a number of autonomic investigations, principally
pupillary reflex studies but also a single sympathetic cardiovascular reflex function test.
Although there were no significant differences in the pupillary measures, there were a
significantly lower number of normal BP responses to isometric hand-grip in patients
with fatigue as compared to those without. This does raise the possibility of autonomic
dysfunction contributing to MS-fatigue.
The primary aim of the final study again derived from the results of the
first and second studies, that of pathology within deep grey matter structures in MS. It is
generally agreed that multidisciplinary approaches to MS-fatigue management are most
appropriate and also that convincing evidence for specific pharmacological agents does
not exist. Studies in MS-fatigue are complicated by the reliance on subjective measures
of fatigue and certainly these tools have, so far, provided conflicting evidence in limited
studies of modafinil. Although its mechanism is yet to be clarified, evidence supports an
interaction with the arousal network involving a number of deep grey matter and
brainstem nuclei. In this study neurophysiological and laboratory measures of alertness,
principally pupillography as well as non-pupillary measures of vigilance, were utilised to
explore more objectively the role of modafinil. It was demonstrated that in MS patients
with fatigue, there was a significant improvement with modafinil, as compared to
placebo, in a number of these measures including the Plfl, power of pupil fluctuations,
CFFF threshold and speech-pause time. Furthermore, this was not simply a class effect
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but rather specific to fatigue sufferers. This supports a role for modafinil in MS-fatigue
management potentially through its effect on the arousal network.
6.2 Conclusions
The principal aim of this thesis was to investigate the potential role of deep grey matter
structures in MS-fatigue. It was a broad aim and for that it may be open to criticism.
Similarly, the use of a number of investigational tools within the thesis may also provoke
comment. However, fatigue is a rather heterogenous, poorly-described symptom in
clinical practice and, by common consensus, has a multifactorial basis both between and
often also within MS patients. It therefore represents a challenging area to study for the
MS research community and a heterogenous approach may be considered a strength and
necessity.
This thesis also represents a body of work which evolved as the studies
were completed. Initially quantitative MRI-based studies were employed and, in light of
its ability to detect subtle abnormalities, were expanded to other deep grey matter areas.
Subsequent to abnormalities being determined in the hypothalamus, alternative laboratory
tools were utilised to explore additional pathophysiological mechanisms. Finally,
considering the expanding knowledge base of its mode of action and its current favour, it
was appropriate to investigate the role of modafinil in fatigue. However, rather than
repeat subjective questionnaire-based studies, a study incorporating objective measures
was devised to attempt to reduce the well established criticisms of fatigue studies.
In the first two studies, through applying a method of T I relaxation time
measurement that had been shown in previous studies to be effective in demonstrating
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pathology in pyramidal tracts and the cervical spinal cord, we revealed abnormalities in
three deep grey structures, the thalamus, putamen and hypothalamus[139, 140]. This
supported the use of this technique in expanding the knowledge of disease burden in MS
as abnormal T I relaxation time measurements in the deep grey matter had not been
previously demonstrated in RRMS. In addition, non-conventional MRI techniques had
never previously been used to investigate the hypothalamus in MS. The presence of
abnormalities in these structures that are well interconnected raises the possibility of a
common diffuse process accounting for this pathology. Wallerian degeneration, thought
to account for pathology in NAWM, would be most readily considered although only
limited evidence existed in these studies for this theory.
Inchapter 2, it was also shown that the TI value of the thalamus correlated
significantly with fatigue severity with bigher thalamic TI values occurring in patient
with fatigue as compared to those without. The conventional measure of disease burden,
T2-lesion volume, was not associated with fatigue and nor were the TI relaxation times
of other deep grey matter structures. This would support the concept raised by previous
studies in MS that suggest the spatial localization of pathology is more important than the
overall disease burden in accounting for clinical features. Similarly, it also supports the
theory that non-conventional MRI modalities may be more relevant in terms of
addressing the clinical-radiological paradox.
In chapter 3, we reported no association between the pathology detected in
the hypothalamus and fatigue severity. However, in light of the number of mechanisms
that exist by which the hypothalamus could affect fatigue, further studies specifically to
address individual mechanism were performed. In the study detailed in chapter 4, we
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found no relationship between CSF hypocretin-l levels and fatigue or hypersomnolence
in MS. This was notably a prospective study but with a number of methodological flaws.
Patients were neither age- nor sex-matched and potential conditions or treatments which
could contribute to secondary fatigue were not addressed. In addition, there was a degree
of selection bias as to the patients enrolled who were undergoing an LP for management
of their condition rather than primarily as part of the study.
In the study detailed in chapter 5 we demonstrated a significantly lower
number of normal responses on a sympathetic cardiovascular reflex test in patients with
fatigue as compared to those without. It is possible that the abnormalities in the
hypothalamus detected in chapter 3 may account for this autonomic disturbance.
In the final study we demonstrated a significant response to modafinil, as
compared to placebo, in MS fatigue sufferers in two measures of alertness on
pupillography. We also detected significant improvement in other, non-pupillary,
measures of alertness including; CFFF threshold, a measure of CNS vigilance and the
pause time on speech analysis, a sensitive measure of psychomotor retardation. These
responses were not a class effect in this study and these measures were not significantly
different at baseline in this cohort as compared to patients without fatigue or healthy
controls. This study therefore provides support for the use of modafinil in MS-fatigue.
Overall a number of conclusions may be drawn from this thesis. Firstly,
deep grey matter structures, whilst frequently appearing normal on conventional MRI, are
involved in MS. Furthermore, this pathology may contribute to MS-fatigue possibly
through abnormalities within nuclei or their connections that are involved in cortico-
subcortical circuits. It appears likely that non-conventional MRI techniques are required
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to both demonstrate pathology and highlight the specific localisation of pathology
relevant to clinical features.
There is also evidence of abnormal sympathetic autonomic tests in MS
patients with fatigue and this is potentially due to more frequent hypothalamic
involvement in MS than that appreciated by conventional MRI. Only a single
cardiovascular reflex test was performed and as such we are unable to determine whether
there is true autonomic dysfunction. Although, in the same cohort. further pupillary
autonomic investigations were not different between fatigue and non-fatigue sufferers, it
would certainly be more likely that cardiovascular, as opposed to alternative autonomic
system dysfunction would contribute to fatigue. Pathology within the hypothalamus, as
demonstrated by abnormal TI values, could certainly account for autonomic
abnormalities. This pathology could potentially also lead to disturbance of other
hypothalamic functions. However, it appears that, other than rare acute cases, the
hypocretin pathway is not frequently impaired in MS and nor does it appear to be a
significant or frequent contributor to MS-fatigue.
We have demonstrated robust evidence of the effectiveness ofmodafinil in
MS-fatigue sufferers. Modafinil is classed as a wakefulness-promoting drug and as such
is principally used in hypersomnolent conditions. Its role in MS-fatigue management has,
therefore, never been clear. However, modafinil does appear to act on areas of the brain
which are involved in MS. In addition, whilst severe, acute hypersomnolence is a rare
syndrome inMS, it does appear that tmgue and at the very least a perception of EDS
may coexist in MS. It may be that this perception is in fact the lack of alertness and
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vigilance with fatigue that we have demonstrated to respond to modafinil on
neurophysiological and laboratory measures.
As I have discussed throughout this thesis, MS-fatigue almost certainly has
a heterogenous basis. For this reason, it certainly cannot be stated that modafinil will be
effective for all fatigue sufferers. Nevertheless, modafinil on the strength of our study
will contribute positively towards fatigue management in MS patients. However, in light
of its multifactorial nature, it might be necessary to try and clarify if there are any specific
characteristics these fatigue sufferers possess which leads to this modafinil response.
6.1.1 Recent MRI litentare of grey matter involvement in MS
There have been a number of more recent studies that have evaluated Tl relaxation time
measurements in MS since the studies I have detailed in chapters 2 and 3. In addition an
increasing body of literature has developed evaluating the impact of grey matter
involvement in MS. I intend to discuss this in more detail in order that the MRI studies
described in this thesis are seen in a more up-to-date context and prior to discussing
future potential developments and applications.
Longitudinal studies have been reported of T 1 relaxation time
measurements in NAWM and normal-appearing grey matter (NAGM) in both early RR-
and PPMS cohorts[138, 188]. Baseline resuhs in these studies have shown significantly
bigher T! values in both grey and white matter fractions in MS patients as compared to
healthy controls. This MRI technique bas also demonstrated a significant change in
NAWM and NAGM over even a relatively short period of time in the early PPMS cohort
although this was not found in RRMS patients. In PPMS, this increase in pathology
184
demonstrated by T 1 measurements correlated significantly with the degree of change in
clinical deficit, in particular walking ability. This was despite relatively small changes in
the clinical measures[138]. Further assessment of the clinical relevance of cortical and
deep grey matter involvement in MS has been studied principally with non-conventional
MRI techniques other than Tl relaxation time measurements.
Studies have reported abnormal grey matter MTR measurements through
employing either global or regional NAGM analysis in cohorts of RR- and SPMS
patients[189, 190]. In addition, significant associations were found between grey matter
MTR measures and locomotor ability and, furthermore, it was shown that this grey matter
pathology was a better predictor of clinical outcome than that found in NAWM[189].
Grey matter pathology has also been demonstated, using Mm analysis, in PPMS patients
including those with only a short disease duration[191, 192]. The clinical relevance of the
damage detected in NAGM in PPMS was eloquently demonstrated in a study by Khaleeli
et aI in which an association was found between abnormal Mm measurements in the
motor cortex and performance in the motor components of the Multiple Sclerosis
Functional Composite as well as EDSS scores[191].
Cortical and deep grey matter volume measurements have also provided
evidence of the clinical impact of grey matter involvement in MS. Grey matter atrophy
has been demonstrated in both RR- and SPMS patients and was associated with degree of
disability[ 193, 194]. In addition, as compared to white matter, the rate of grey matter
atrophy increased significantly with advancing disease[193]. A number of studies have
assessed the role of grey matter involvement in cognitive dysfunction. Sanfilipo et al
demonstrated impaired performance in a number of neuropsychological tests in MS
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patients[194]. They also found a differential affect of grey and white matter atrophy on
performance with white matter volume predicting working memory and processing speed
and grey matter volume associated with verbal memory. Specific regional grey matter
atrophy and its role in cognitive function was investigated in a further study on RR- and
SPMS patients[195]. Deep grey matter, in particular thalamic, atrophy, was associated
with impairment in processing speed whilst atrophy of the amygdala correlated with
verbal memory performance.
Regional grey matter abnormalities have also been eloquently
demonstrated with advanced MRI techniques in the cervical spinal cord and cerebellum.
Agosta et al found magnetization transfer MRI-detectable damage in the grey matter of
macroscopically-normal, cervical spinal cord in a cohort of RRMS patients[ 196].
Furthermore, this pathology was associated with disability as measured by the EDSS.
Cerebellar grey matter atrophy has been demonstrated by Anderson et al in SPMS with
lower volumes in patients with cerebellar dysfunction and an association between atrophy
and upper limb function as measured by the nine-hole peg test[197].
Finally, there are a number of more recent studies employing non-
conventional MRI techniques to further explore the potential role of grey matter in MS-
fatigue. Tedeschi et at demonstrated that in a large cohort of RRMS patients with low
disability scores, patients with fatigue had significantly greater global grey and white
matter atrophy as compared to those without fatigue[198]. Investigations of focal grey
matter atrophy have however had mixed results in studies involving smaller numbers of
MS patients. Benedict et al reported no association between FSS scores and volume
measurements in deep (thalamus and caudate) and cortical (amygdala and hippocampus)
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grey matter regions[195]. On the otherhand, Sepulcre at al found a significant association
between fatigue severity and cortical, predominantly frontal region, atrophy[ 199].
Therefore, through advanced MRI techniques, there is an ever-increasing
body of evidence of grey matter involvement in MS and its clinical impact both in terms
of locomotor disability, cognitive dysfunction and fatigue.
6.2.2 Potential developments and future applications from this thesis
Larger patient cohorts will be necessary to further evaluate the techniques, results and
conclusions of this thesis. Additional development of techniques may also be appropriate.
This process is, in part, already underway. Our group has already submitted a study for
publication in which the MRI analysis of the hypothalamus has been adapted. ROIs were
delineated on high-resolution MP-RAGE images, prior to co-registering these ROIs on
the TI map images. The MP-RAGE sequences have the advantage, over the method
described in this thesis, of providing a somewhat better anatomical view of structures
such as the hypothalamus. Upon applying this to a slightly larger cohort of RRMS
patients, significantly higher T 1 values were again found in the hypothalamus, as
compared to healthy individuals. In addition a further quantitative MR.I measure,
hypothalamic volume, was determined although no significant difference was found. This
study also detected a significant correlation between fatigue severity and T 1 relaxation
time. These results may also require further evaluation and clarification with larger
cohorts. In addition, possibly using techniques described in this thesis, it would be
appropriate to attempt to determine by which mechanism pathology in the hypothalamus
contributes to fatigue.
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The application of neurophysiological and laboratory measures of alertness
more often in fatigue studies has to be considered. We utilised a number of measures,
however, it would seem appropriate to be more selective as the overriding advantage of
questionnaires is that they are a quick, low-technology solution. Pupillography is well
established and is not time consuming. It requires a small amount of equipment and a
separate room but, for the researcher, performing the investigation is very
straightforward. Performing speech analysis is quicker than completing the FSS and it is
also relatively low-tech. It is a sensitive measure although as speech is highly
individualistic, analysis has to be performed intra- rather than inter-cohort. Determining
CFFF threshold is also quick and low-tech but in MS is confounded by its possible dual
detection of visual dysfunction.
Whilst these measures are robust and provide objective evidence, it remains
important to be aware that these measures may not completely correlate with patient's
symptoms and in particular quality of life (QoL). In view of its significant impact, QoL
tools should run alongside objective assessments when determining the effectiveness of
treatments for fatigue. A future study of modafinil would be appropriate with a larger
cohort, possibly a more limited number of objective investigations and a sensitive QoL
measure. A larger patient cohort study of modafinil would have the potential to identify
factors which may influence response to treatment. It is apparent that the way forward in
the management of MS-fatigue will be to identify specific features or characteristics,
whether clinical, MRI, CSF or laboratory, which can lead to a tailored fatigue treatment
program for the individual.
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Appendix 1. Fatigue Severity Scale
Read each of the following 9 statements and circle a number from 1 to 7 based on how
accurately it reflects your condition and the extent to which you agree or disagree that the
statement applies to you. A low value (e.g. 1) indicates strong disagreement and a high
value (e.g, 7) strong agreement with the statement.
• My motivation is lower when I am fatigued
• Exercise brings on my fatigue
• I am easily fatigued
• Fatigue interferes with my physical functioning
• Fatigue causes frequent problems for me
• My fatigue prevents sustained physical functioning
• Fatigue interferes with carrying out certain duties and responsibilities
• Fatigue is amongst my three most disabling symptoms
• Fatigue interferes with my work, family, or social life
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Appendix 2. Epworth Sleepiness Scale
Consider the following situations, how likely are you to doze off or fall asleep, in contrast
to feeling just tired? Even if you have not done some of these things recently try to work
out how they would have affected you. Use the following scale to choose the most
appropriate number for each situation:
o =would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing
• Sitting and reading
• Watching TV
• Sitting inactive in a public place (e.g. a theatre or a meeting)
• As a passenger in a car for an hour without a break
• Lying down to restin the afternoon when circumstances permit
• Sitting and talking to someone
• Sitting quietly after a lunch without alcohol
• Ina car, whilst stopped for a few minutes in the traffic
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Appendix 3. Ethics approval
The studies described in chapters' 2 through 5 were performed on healthy volunteers and
patients following the approval of the Nottingham Research Ethics Committee. Reference
numbers: NS 10020 1 and NS090 102. In addition, the study in chapter 5 was approved by
the Medicines Control Agency. Reference number: MF 8000112346.
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